

TDMS No. 20011 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 07/09/2008

Time Report Requested: 10:20:06

First Dose M/F: 07/14/03 / 07/14/03

Lab: BNW

C Number: C20011
Lock Date: 06/15/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 20011 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 07/09/2008

Time Report Requested: 10:20:06

First Dose M/F: 07/14/03 / 07/14/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF 1-Bromopropane

MALE RATS

Organ

Adrenal Cortex

Bone

Harderian Gland

Heart

Heart: Atrium

Kidney: Pelvis

Larynx

Liver

Lung

Lymph Node, Bronchial

Lymph Node, Mediastinal

Nose

Nose: Glands

Pancreas: Acinus

Parathyroid Gland

Pituitary Gland

Preputial Gland

Prostate

Salivary Glands

Skin

Spleen

FEMALE RATS

Organ

Clitoral Gland

Morphology

Vacuolization Cytoplasmic

Inflammation Chronic

Inflammation Chronic

Cardiomyopathy

Thrombosis

Inflammation Chronic

Foreign Body

Inflammation Chronic

Clear Cell Focus

Hepatodiaphragmatic Nodule

Inflammation Chronic

Hyperplasia Lymphoid

Angiectasis

Inflammation Chronic

Hyperplasia

Atrophy

Hyperplasia

Hemorrhage

Hyperplasia

Inflammation Chronic

Hyperplasia

Inflammation Chronic

Hyperkeratosis

Inflammation Chronic

Hematopoietic Cell Proliferation

Hemorrhage Chronic

Infarct Chronic

Morphology

Hyperplasia

TDMS No. 20011 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 07/09/2008

Time Report Requested: 10:20:06

First Dose M/F: 07/14/03 / 07/14/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF 1-Bromopropane

Harderian Gland	Inflammation Chronic
Heart	Cardiomyopathy
Islets, Pancreatic	Hyperplasia
Larynx	Inflammation Chronic
	Metaplasia
Liver	Clear Cell Focus
	Vacuolization Cytoplasmic
Lung	Inflammation Chronic
Lymph Node, Bronchial	Angiectasis
Lymph Node, Mediastinal	Angiectasis
	Hemorrhage
Nose	Inflammation Chronic
Nose: Glands	Hyperplasia
Nose: Olfactory Epithelium	Metaplasia Respiratory
Nose: Respiratory Epithelium	Hyperplasia
	Metaplasia
Oral Mucosa	Foreign Body
	Inflammation Chronic
Spleen	Hematopoietic Cell Proliferation
Stomach, Forestomach	Hyperplasia
	Ulcer
Trachea	Inflammation Chronic
Trachea: Epithelium	Hyperplasia
Uterus	Decidual Reaction

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	27/50 (54%)	21/50 (42%)	22/50 (44%)	20/50 (40%)
POLY-3 RATE (b)	27/44.60	21/41.68	22/41.74	20/38.05
POLY-3 PERCENT (g)	60.5%	50.4%	52.7%	52.6%
TERMINAL (d)	15/23 (65%)	18/26 (69%)	8/18 (44%)	7/13 (54%)
FIRST INCIDENCE	582	528	418	624

STATISTICAL TESTS

POLY 3	P=0.299N	P=0.221N	P=0.294N	P=0.296N
POLY 1.5	P=0.218N	P=0.191N	P=0.254N	P=0.202N
POLY 6	P=0.421N	P=0.275N	P=0.350N	P=0.447N
COCH-ARM / FISHERS	P=0.135N	P=0.158N	P=0.212N	P=0.115N
MAX-ISO-POLY-3	P=0.359N	P=0.168N	P=0.229N	P=0.237N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Cortex
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	9/50 (18%)	16/50 (32%)	9/50 (18%)	12/50 (24%)
POLY-3 RATE (b)	9/42.98	16/42.77	9/38.92	12/38.01
POLY-3 PERCENT (g)	20.9%	37.4%	23.1%	31.6%
TERMINAL (d)	4/23 (17%)	9/26 (35%)	3/18 (17%)	5/13 (39%)
FIRST INCIDENCE	501	562	603	577

STATISTICAL TESTS

POLY 3	P=0.313	P=0.070	P=0.511	P=0.199
POLY 1.5	P=0.379	P=0.073	P=0.550	P=0.241
POLY 6	P=0.241	P=0.073	P=0.466	P=0.155
COCH-ARM / FISHERS	P=0.477	P=0.083	P=0.602N	P=0.312
MAX-ISO-POLY-3	P=0.249	P=0.043*	P=0.407	P=0.148

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	23/50 (46%)	18/50 (36%)	23/50 (46%)	19/50 (38%)
POLY-3 RATE (b)	23/44.02	18/42.60	23/40.99	19/40.46
POLY-3 PERCENT (g)	52.2%	42.3%	56.1%	47%
TERMINAL (d)	12/23 (52%)	10/26 (39%)	12/18 (67%)	5/13 (39%)
FIRST INCIDENCE	582	562	520	422

STATISTICAL TESTS

POLY 3	P=0.479N	P=0.230N	P=0.442	P=0.391N
POLY 1.5	P=0.415N	P=0.223N	P=0.505	P=0.337N
POLY 6	P=0.517	P=0.238N	P=0.354	P=0.469N
COCH-ARM / FISHERS	P=0.340N	P=0.208N	P=0.579N	P=0.272N
MAX-ISO-POLY-3	P=0.500N	P=0.173N	P=0.358	P=0.315N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Bone
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/41.44	0/40.69	0/37.74	2/36.62
POLY-3 PERCENT (g)	0%	0%	0%	5.5%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	---	---	484

STATISTICAL TESTS

POLY 3	P=0.040*	(e)	(e)	P=0.210
POLY 1.5	P=0.042*	(e)	(e)	P=0.221
POLY 6	P=0.037*	(e)	(e)	P=0.196
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Brain
Hemorrhage**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/42.05	1/41.23	2/38.13	2/36.30
POLY-3 PERCENT (g)	2.4%	2.4%	5.3%	5.5%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	534	562	666	660

STATISTICAL TESTS

POLY 3	P=0.278	P=0.757	P=0.466	P=0.449
POLY 1.5	P=0.303	P=0.757	P=0.480	P=0.470
POLY 6	P=0.249	P=0.758	P=0.448	P=0.423
COCH-ARM / FISHERS	P=0.337	P=0.753N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.408	P=0.494	P=0.261	P=0.253

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Coagulating Gland
Inflammation**

LESION RATES

OVERALL (a)	2/3 (67%)	0/0 (0%)	0/1 (0%)	0/2 (0%)
POLY-3 RATE (b)	2/3.00	0/0.00	0/1.00	0/0.98
POLY-3 PERCENT (g)	66.7%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)
FIRST INCIDENCE	635	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	P=0.500N	P=0.506N
POLY 1.5	(e)	(e)	P=0.500N	P=0.422N
POLY 6	(e)	(e)	P=0.500N	P=0.583N
COCH-ARM / FISHERS	P=0.130N	(e)	P=0.500N	P=0.300N
MAX-ISO-POLY-3	(e)	(e)	P=0.207N	P=0.254N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Eye
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/41.24	0/40.61	1/37.74	2/36.95
POLY-3 PERCENT (g)	0%	0%	2.7%	5.4%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	---	---	729 (T)	422

STATISTICAL TESTS

POLY 3	P=0.059	(e)	P=0.482	P=0.213
POLY 1.5	P=0.064	(e)	P=0.491	P=0.225
POLY 6	P=0.052	(e)	P=0.471	P=0.199
COCH-ARM / FISHERS	P=0.072	(e)	P=0.505	P=0.253
MAX-ISO-POLY-3	P=0.078	(e)	P=0.159	P=0.076

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Eye: Lens
Cataract**

LESION RATES

OVERALL (a)	2/49 (4%)	0/49 (0%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	2/41.24	0/40.61	3/38.38	2/36.56
POLY-3 PERCENT (g)	4.9%	0%	7.8%	5.5%
TERMINAL (d)	2/23 (9%)	0/26 (0%)	2/18 (11%)	1/13 (8%)
FIRST INCIDENCE	729 (T)	---	520	453

STATISTICAL TESTS

POLY 3	P=0.367	P=0.240N	P=0.467	P=0.650
POLY 1.5	P=0.394	P=0.239N	P=0.485	P=0.672
POLY 6	P=0.333	P=0.239N	P=0.446	P=0.622
COCH-ARM / FISHERS	P=0.432	P=0.247N	P=0.510	P=0.684N
MAX-ISO-POLY-3	P=0.323	P=0.079N	P=0.301	P=0.453

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Harderian Gland
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/41.44	0/40.69	0/37.74	2/36.64
POLY-3 PERCENT (g)	0%	0%	0%	5.5%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	---	---	453

STATISTICAL TESTS

POLY 3	P=0.040*	(e)	(e)	P=0.210
POLY 1.5	P=0.042*	(e)	(e)	P=0.221
POLY 6	P=0.037*	(e)	(e)	P=0.196
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	26/50 (52%)	23/50 (46%)	23/50 (46%)	15/50 (30%)
POLY-3 RATE (b)	26/44.30	23/42.33	23/41.39	15/38.01
POLY-3 PERCENT (g)	58.7%	54.3%	55.6%	39.5%
TERMINAL (d)	17/23 (74%)	17/26 (65%)	11/18 (61%)	7/13 (54%)
FIRST INCIDENCE	429	569	520	527

STATISTICAL TESTS

POLY 3	P=0.047N*	P=0.420N	P=0.469N	P=0.054N
POLY 1.5	P=0.030N*	P=0.396N	P=0.417N	P=0.036N*
POLY 6	P=0.081N	P=0.429N	P=0.522N	P=0.085N
COCH-ARM / FISHERS	P=0.016N*	P=0.345N	P=0.345N	P=0.021N*
MAX-ISO-POLY-3	P=0.069N	P=0.337N	P=0.381N	P=0.042N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Heart: Atrium
Thrombosis**

LESION RATES

OVERALL (a)	4/50 (8%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	4/42.29	0/40.69	0/37.74	2/36.06
POLY-3 PERCENT (g)	9.5%	0%	0%	5.6%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	646	---	---	659

STATISTICAL TESTS

POLY 3	P=0.340N	P=0.065N	P=0.075N	P=0.412N
POLY 1.5	P=0.337N	P=0.063N	P=0.068N	P=0.380N
POLY 6	P=0.346N	P=0.066N	P=0.086N	P=0.458N
COCH-ARM / FISHERS	P=0.337N	P=0.059N	P=0.059N	P=0.339N
MAX-ISO-POLY-3	P=0.076N	P=0.023N*	P=0.032N*	P=0.275N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	10/50 (20%)	7/50 (14%)	6/50 (12%)	9/50 (18%)
POLY-3 RATE (b)	10/42.86	7/41.46	6/38.78	9/38.21
POLY-3 PERCENT (g)	23.3%	16.9%	15.5%	23.6%
TERMINAL (d)	5/23 (22%)	5/26 (19%)	4/18 (22%)	1/13 (8%)
FIRST INCIDENCE	591	568	534	453

STATISTICAL TESTS

POLY 3	P=0.509	P=0.320N	P=0.268N	P=0.595
POLY 1.5	P=0.549	P=0.312N	P=0.239N	P=0.567N
POLY 6	P=0.453	P=0.326N	P=0.314N	P=0.540
COCH-ARM / FISHERS	P=0.500N	P=0.298N	P=0.207N	P=0.500N
MAX-ISO-POLY-3	P=0.480	P=0.233N	P=0.196N	P=0.490

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Islets, Pancreatic
Metaplasia Hepatocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/41.44	0/40.69	0/37.74	0/35.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney
Nephropathy Chronic**

LESION RATES

OVERALL (a)	44/50 (88%)	45/50 (90%)	39/50 (78%)	44/49 (90%)
POLY-3 RATE (b)	44/47.89	45/46.75	39/44.62	44/45.75
POLY-3 PERCENT (g)	91.9%	96.3%	87.4%	96.2%
TERMINAL (d)	23/23 (100%)	26/26 (100%)	17/18 (94%)	13/13 (100%)
FIRST INCIDENCE	534	528	514	422

STATISTICAL TESTS

POLY 3	P=0.358	P=0.287	P=0.333N	P=0.301
POLY 1.5	P=0.450	P=0.373	P=0.220N	P=0.383
POLY 6	P=0.266	P=0.204	P=0.563N	P=0.244
COCH-ARM / FISHERS	P=0.553N	P=0.500	P=0.143N	P=0.514
MAX-ISO-POLY-3	P=0.250	P=0.141	P=0.210N	P=0.153

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney: Cortex, Renal Tubule
Casts Granular**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/41.44	0/40.69	2/38.63	0/35.06
POLY-3 PERCENT (g)	0%	0%	5.2%	0%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	---	578	---

STATISTICAL TESTS

POLY 3	P=0.513	(e)	P=0.221	(e)
POLY 1.5	P=0.547	(e)	P=0.228	(e)
POLY 6	P=0.468	(e)	P=0.214	(e)
COCH-ARM / FISHERS	P=0.591	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.267	(e)	P=0.075	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney: Pelvis
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/49 (4%)
POLY-3 RATE (b)	0/41.44	0/40.69	0/37.74	2/35.17
POLY-3 PERCENT (g)	0%	0%	0%	5.7%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	---	---	---	701

STATISTICAL TESTS

POLY 3	P=0.038*	(e)	(e)	P=0.202
POLY 1.5	P=0.040*	(e)	(e)	P=0.214
POLY 6	P=0.035*	(e)	(e)	P=0.187
COCH-ARM / FISHERS	P=0.045*	(e)	(e)	P=0.242
MAX-ISO-POLY-3	P=0.031*	(e)	(e)	P=0.074

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Larynx
Foreign Body

LESION RATES

OVERALL (a)	6/50 (12%)	1/50 (2%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	6/42.19	1/41.06	5/39.05	1/36.42
POLY-3 PERCENT (g)	14.2%	2.4%	12.8%	2.8%
TERMINAL (d)	3/23 (13%)	0/26 (0%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	501	624	561	527

STATISTICAL TESTS

POLY 3	P=0.126N	P=0.059N	P=0.555N	P=0.081N
POLY 1.5	P=0.111N	P=0.059N	P=0.532N	P=0.070N
POLY 6	P=0.150N	P=0.057N	P=0.579N	P=0.098N
COCH-ARM / FISHERS	P=0.095N	P=0.056N	P=0.500N	P=0.056N
MAX-ISO-POLY-3	P=0.064N	P=0.026N*	P=0.427N	P=0.046N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Larynx
Inflammation Chronic**

LESION RATES

OVERALL (a)	21/50 (42%)	28/50 (56%)	31/50 (62%)	27/50 (54%)
POLY-3 RATE (b)	21/44.09	28/45.59	31/45.51	27/44.93
POLY-3 PERCENT (g)	47.6%	61.4%	68.1%	60.1%
TERMINAL (d)	11/23 (48%)	13/26 (50%)	9/18 (50%)	6/13 (46%)
FIRST INCIDENCE	501	560	488	394

STATISTICAL TESTS

POLY 3	P=0.169	P=0.127	P=0.032*	P=0.157
POLY 1.5	P=0.170	P=0.115	P=0.031*	P=0.156
POLY 6	P=0.170	P=0.164	P=0.042*	P=0.165
COCH-ARM / FISHERS	P=0.175	P=0.115	P=0.036*	P=0.158
MAX-ISO-POLY-3	P=0.080	P=0.091	P=0.021*	P=0.112

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Larynx
Metaplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	6/50 (12%)	8/50 (16%)	5/50 (10%)
POLY-3 RATE (b)	4/42.14	6/42.36	8/40.43	5/37.07
POLY-3 PERCENT (g)	9.5%	14.2%	19.8%	13.5%
TERMINAL (d)	2/23 (9%)	2/26 (8%)	1/18 (6%)	1/13 (8%)
FIRST INCIDENCE	501	585	561	562

STATISTICAL TESTS

POLY 3	P=0.332	P=0.372	P=0.153	P=0.419
POLY 1.5	P=0.381	P=0.367	P=0.162	P=0.452
POLY 6	P=0.278	P=0.388	P=0.148	P=0.383
COCH-ARM / FISHERS	P=0.455	P=0.370	P=0.178	P=0.500
MAX-ISO-POLY-3	P=0.313	P=0.254	P=0.095	P=0.300

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/41.44	2/40.69	1/37.87	0/35.80
POLY-3 PERCENT (g)	0%	4.9%	2.6%	0%
TERMINAL (d)	0/23 (0%)	2/26 (8%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	729 (T)	697	---

STATISTICAL TESTS

POLY 3	P=0.514N	P=0.233	P=0.482	(e)
POLY 1.5	P=0.492N	P=0.234	P=0.490	(e)
POLY 6	P=0.545N	P=0.233	P=0.472	(e)
COCH-ARM / FISHERS	P=0.461N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.355	P=0.075	P=0.158	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	9/50 (18%)	9/50 (18%)	8/50 (16%)	8/50 (16%)
POLY-3 RATE (b)	9/41.83	9/41.08	8/37.74	8/35.93
POLY-3 PERCENT (g)	21.5%	21.9%	21.2%	22.3%
TERMINAL (d)	7/23 (30%)	8/26 (31%)	8/18 (44%)	7/13 (54%)
FIRST INCIDENCE	653	618	729 (T)	697

STATISTICAL TESTS

POLY 3	P=0.525	P=0.589	P=0.595N	P=0.578
POLY 1.5	P=0.508N	P=0.591	P=0.552N	P=0.580N
POLY 6	P=0.428	P=0.594	P=0.567	P=0.498
COCH-ARM / FISHERS	P=0.424N	P=0.602N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.714	P=0.482	P=0.486N	P=0.469

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	16/50 (32%)	25/50 (50%)	17/50 (34%)	15/50 (30%)
POLY-3 RATE (b)	16/42.40	25/41.09	17/39.08	15/37.44
POLY-3 PERCENT (g)	37.7%	60.8%	43.5%	40.1%
TERMINAL (d)	11/23 (48%)	23/26 (89%)	13/18 (72%)	8/13 (62%)
FIRST INCIDENCE	635	627	514	562

STATISTICAL TESTS

POLY 3	P=0.397N	P=0.022*	P=0.377	P=0.507
POLY 1.5	P=0.312N	P=0.031*	P=0.433	P=0.577
POLY 6	P=0.527N	P=0.012*	P=0.299	P=0.412
COCH-ARM / FISHERS	P=0.221N	P=0.052	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.273	P=0.013*	P=0.300	P=0.416

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Degeneration Cystic**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	2/41.44	2/40.95	1/38.44	4/35.80
POLY-3 PERCENT (g)	4.8%	4.9%	2.6%	11.2%
TERMINAL (d)	2/23 (9%)	1/26 (4%)	0/18 (0%)	4/13 (31%)
FIRST INCIDENCE	729 (T)	660	488	729 (T)

STATISTICAL TESTS

POLY 3	P=0.184	P=0.690	P=0.526N	P=0.271
POLY 1.5	P=0.202	P=0.690	P=0.515N	P=0.298
POLY 6	P=0.162	P=0.695	P=0.541N	P=0.236
COCH-ARM / FISHERS	P=0.227	P=0.691N	P=0.500N	P=0.339
MAX-ISO-POLY-3	P=0.176	P=0.494	P=0.308N	P=0.167

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
Hepatodiaphragmatic Nodule

LESION RATES

OVERALL (a)	4/50 (8%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	4/41.70	1/40.69	0/37.74	2/36.40
POLY-3 PERCENT (g)	9.6%	2.5%	0%	5.5%
TERMINAL (d)	3/23 (13%)	1/26 (4%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	660	729 (T)	---	635

STATISTICAL TESTS

POLY 3	P=0.294N	P=0.185N	P=0.073N	P=0.401N
POLY 1.5	P=0.286N	P=0.184N	P=0.067N	P=0.374N
POLY 6	P=0.305N	P=0.184N	P=0.081N	P=0.435N
COCH-ARM / FISHERS	P=0.279N	P=0.181N	P=0.059N	P=0.339N
MAX-ISO-POLY-3	P=0.128N	P=0.090N	P=0.030N*	P=0.264N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/41.70	1/40.69	3/37.90	0/35.80
POLY-3 PERCENT (g)	4.8%	2.5%	7.9%	0%
TERMINAL (d)	1/23 (4%)	1/26 (4%)	2/18 (11%)	0/13 (0%)
FIRST INCIDENCE	660	729 (T)	688	---

STATISTICAL TESTS

POLY 3	P=0.296N	P=0.509N	P=0.456	P=0.272N
POLY 1.5	P=0.272N	P=0.506N	P=0.475	P=0.257N
POLY 6	P=0.332N	P=0.509N	P=0.431	P=0.294N
COCH-ARM / FISHERS	P=0.242N	P=0.500N	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.235N	P=0.290N	P=0.293	P=0.109N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/41.98	1/41.17	1/37.87	1/36.06
POLY-3 PERCENT (g)	4.8%	2.4%	2.6%	2.8%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	646	585	697	659

STATISTICAL TESTS

POLY 3	P=0.446N	P=0.507N	P=0.536N	P=0.553N
POLY 1.5	P=0.430N	P=0.505N	P=0.520N	P=0.531N
POLY 6	P=0.468N	P=0.506N	P=0.557N	P=0.582N
COCH-ARM / FISHERS	P=0.409N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.494N	P=0.288N	P=0.319N	P=0.336N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	31/50 (62%)	38/50 (76%)	32/50 (64%)	37/50 (74%)
POLY-3 RATE (b)	31/46.22	38/47.40	32/46.52	37/46.10
POLY-3 PERCENT (g)	67.1%	80.2%	68.8%	80.3%
TERMINAL (d)	15/23 (65%)	24/26 (92%)	11/18 (61%)	12/13 (92%)
FIRST INCIDENCE	429	316	418	394

STATISTICAL TESTS

POLY 3	P=0.160	P=0.100	P=0.519	P=0.099
POLY 1.5	P=0.181	P=0.099	P=0.511	P=0.113
POLY 6	P=0.137	P=0.099	P=0.528	P=0.082
COCH-ARM / FISHERS	P=0.219	P=0.097	P=0.500	P=0.142
MAX-ISO-POLY-3	P=0.097	P=0.065	P=0.425	P=0.061

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung
 Hemorrhage**

LESION RATES

OVERALL (a)	2/50 (4%)	5/50 (10%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/42.38	5/40.94	1/38.24	1/35.80
POLY-3 PERCENT (g)	4.7%	12.2%	2.6%	2.8%
TERMINAL (d)	0/23 (0%)	4/26 (15%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	501	663	578	729 (T)

STATISTICAL TESTS

POLY 3	P=0.253N	P=0.201	P=0.536N	P=0.558N
POLY 1.5	P=0.226N	P=0.206	P=0.520N	P=0.534N
POLY 6	P=0.292N	P=0.198	P=0.556N	P=0.591N
COCH-ARM / FISHERS	P=0.194N	P=0.218	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.257N	P=0.112	P=0.319N	P=0.343N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	5/50 (10%)	0/50 (0%)	1/50 (2%)	6/50 (12%)
POLY-3 RATE (b)	5/43.25	0/40.69	1/38.21	6/39.67
POLY-3 PERCENT (g)	11.6%	0%	2.6%	15.1%
TERMINAL (d)	1/23 (4%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	501	---	590	422

STATISTICAL TESTS

POLY 3	P=0.192	P=0.035N*	P=0.131N	P=0.439
POLY 1.5	P=0.200	P=0.034N*	P=0.118N	P=0.465
POLY 6	P=0.179	P=0.037N*	P=0.150N	P=0.402
COCH-ARM / FISHERS	P=0.210	P=0.028N*	P=0.102N	P=0.500
MAX-ISO-POLY-3	P=0.062	P=0.013N*	P=0.072N	P=0.323

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	15/50 (30%)	11/50 (22%)	13/50 (26%)	11/50 (22%)
POLY-3 RATE (b)	15/44.57	11/42.92	13/40.29	11/38.55
POLY-3 PERCENT (g)	33.7%	25.6%	32.3%	28.5%
TERMINAL (d)	7/23 (30%)	5/26 (19%)	5/18 (28%)	3/13 (23%)
FIRST INCIDENCE	501	505	534	500

STATISTICAL TESTS

POLY 3	P=0.424N	P=0.276N	P=0.538N	P=0.394N
POLY 1.5	P=0.358N	P=0.266N	P=0.483N	P=0.331N
POLY 6	P=0.512N	P=0.285N	P=0.581	P=0.477N
COCH-ARM / FISHERS	P=0.272N	P=0.247N	P=0.412N	P=0.247N
MAX-ISO-POLY-3	P=0.504N	P=0.208N	P=0.447N	P=0.318N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	16/50 (32%)	14/50 (28%)	13/50 (26%)	11/50 (22%)
POLY-3 RATE (b)	16/44.53	14/43.31	13/40.09	11/38.45
POLY-3 PERCENT (g)	35.9%	32.3%	32.4%	28.6%
TERMINAL (d)	7/23 (30%)	7/26 (27%)	5/18 (28%)	3/13 (23%)
FIRST INCIDENCE	501	562	520	484

STATISTICAL TESTS

POLY 3	P=0.281N	P=0.447N	P=0.456N	P=0.315N
POLY 1.5	P=0.221N	P=0.438N	P=0.400N	P=0.256N
POLY 6	P=0.371N	P=0.449N	P=0.530N	P=0.398N
COCH-ARM / FISHERS	P=0.153N	P=0.414N	P=0.330N	P=0.184N
MAX-ISO-POLY-3	P=0.405N	P=0.360N	P=0.371N	P=0.251N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Bronchial
Angiectasis**

LESION RATES

OVERALL (a)	1/3 (33%)	2/6 (33%)	2/5 (40%)	0/8 (0%)
POLY-3 RATE (b)	1/2.29	2/4.76	2/4.11	0/5.41
POLY-3 PERCENT (g)	43.7%	42%	48.6%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	1/1 (100%)	0/2 (0%)
FIRST INCIDENCE	669	660	697	---

STATISTICAL TESTS

POLY 3	P=0.105N	P=0.765N	P=0.743	P=0.301N
POLY 1.5	P=0.105N	P=0.756N	P=0.715	P=0.299N
POLY 6	P=0.088N	P=0.784N	P=0.801	P=0.291N
COCH-ARM / FISHERS	P=0.092N	P=0.762N	P=0.714	P=0.273N
MAX-ISO-POLY-3	P=0.166N	P=0.486N	P=0.460	P=0.060N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Bronchial
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/3 (0%)	0/6 (0%)	0/5 (0%)	4/8 (50%)
POLY-3 RATE (b)	0/2.06	0/4.42	0/3.99	4/6.73
POLY-3 PERCENT (g)	0%	0%	0%	59.4%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/1 (0%)	1/2 (50%)
FIRST INCIDENCE	---	---	---	422

STATISTICAL TESTS

POLY 3	P=0.003**	(e)	(e)	P=0.239
POLY 1.5	P=0.003**	(e)	(e)	P=0.206
POLY 6	P=0.005**	(e)	(e)	P=0.334
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	P=0.212
MAX-ISO-POLY-3	P=0.005**	(e)	(e)	P=0.114

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mediastinal
Angiectasis**

LESION RATES

OVERALL (a)	0/30 (0%)	0/25 (0%)	1/23 (4%)	3/32 (9%)
POLY-3 RATE (b)	0/26.46	0/19.21	1/16.93	3/22.12
POLY-3 PERCENT (g)	0%	0%	5.9%	13.6%
TERMINAL (d)	0/17 (0%)	0/13 (0%)	0/6 (0%)	1/6 (17%)
FIRST INCIDENCE	---	---	418	562

STATISTICAL TESTS

POLY 3	P=0.018*	(e)	P=0.412	P=0.085
POLY 1.5	P=0.023*	(e)	P=0.427	P=0.102
POLY 6	P=0.013*	(e)	P=0.391	P=0.067
COCH-ARM / FISHERS	P=0.030*	(e)	P=0.434	P=0.131
MAX-ISO-POLY-3	P=0.028*	(e)	P=0.139	P=0.036*

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Lymph Node, Mediastinal Hemorrhage

LESION RATES

OVERALL (a)	0/30 (0%)	0/25 (0%)	0/23 (0%)	0/32 (0%)
POLY-3 RATE (b)	0/26.46	0/19.21	0/16.11	0/21.51
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/17 (0%)	0/13 (0%)	0/6 (0%)	0/6 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mediastinal
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/30 (0%)	1/25 (4%)	1/23 (4%)	2/32 (6%)
POLY-3 RATE (b)	0/26.46	1/19.21	1/16.76	2/22.50
POLY-3 PERCENT (g)	0%	5.2%	6%	8.9%
TERMINAL (d)	0/17 (0%)	1/13 (8%)	0/6 (0%)	0/6 (0%)
FIRST INCIDENCE	---	729 (T)	514	500

STATISTICAL TESTS

POLY 3	P=0.129	P=0.436	P=0.410	P=0.201
POLY 1.5	P=0.152	P=0.446	P=0.426	P=0.221
POLY 6	P=0.101	P=0.427	P=0.389	P=0.175
COCH-ARM / FISHERS	P=0.184	P=0.455	P=0.434	P=0.262
MAX-ISO-POLY-3	P=0.143	P=0.145	P=0.139	P=0.076

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mesenteric
Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/41.44	1/40.69	1/37.74	2/36.10
POLY-3 PERCENT (g)	0%	2.5%	2.7%	5.5%
TERMINAL (d)	0/23 (0%)	1/26 (4%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	653

STATISTICAL TESTS

POLY 3	P=0.123	P=0.496	P=0.481	P=0.207
POLY 1.5	P=0.136	P=0.497	P=0.489	P=0.219
POLY 6	P=0.109	P=0.497	P=0.471	P=0.192
COCH-ARM / FISHERS	P=0.153	P=0.500	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.120	P=0.158	P=0.158	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node: Pancreatic
Angiectasis**

LESION RATES

OVERALL (a)	0/5 (0%)	2/5 (40%)	0/5 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/3.36	2/3.82	0/3.29	0/3.40
POLY-3 PERCENT (g)	0%	52.3%	0%	0%
TERMINAL (d)	0/1 (0%)	2/2 (100%)	0/0 (0%)	0/2 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.373N	P=0.217	(e)	(e)
POLY 1.5	P=0.408N	P=0.210	(e)	(e)
POLY 6	P=0.305N	P=0.246	(e)	(e)
COCH-ARM / FISHERS	P=0.445N	P=0.222	(e)	(e)
MAX-ISO-POLY-3	P=0.218N	P=0.056	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Mammary Gland
Galactocele**

LESION RATES

OVERALL (a)	1/40 (3%)	1/36 (3%)	0/39 (0%)	0/36 (0%)
POLY-3 RATE (b)	1/33.39	1/30.32	0/28.95	0/27.87
POLY-3 PERCENT (g)	3%	3.3%	0%	0%
TERMINAL (d)	0/17 (0%)	1/19 (5%)	0/13 (0%)	0/12 (0%)
FIRST INCIDENCE	716	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.260N	P=0.740	P=0.528N	P=0.536N
POLY 1.5	P=0.254N	P=0.738	P=0.519N	P=0.530N
POLY 6	P=0.267N	P=0.744	P=0.541N	P=0.544N
COCH-ARM / FISHERS	P=0.247N	P=0.726	P=0.506N	P=0.526N
MAX-ISO-POLY-3	P=0.297N	P=0.472	P=0.191N	P=0.196N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Mesentery
Necrosis**

LESION RATES

OVERALL (a)	13/13 (100%)	13/13 (100%)	7/8 (88%)	17/19 (89%)
POLY-3 RATE (b)	13/13.00	13/13.00	7/7.98	17/18.37
POLY-3 PERCENT (g)	100%	100%	87.7%	92.6%
TERMINAL (d)	8/8 (100%)	6/6 (100%)	3/3 (100%)	3/3 (100%)
FIRST INCIDENCE	591	611	488	394

STATISTICAL TESTS

POLY 3	P=0.201N	(e)	P=0.408N	P=0.445N
POLY 1.5	P=0.165N	(e)	P=0.405N	P=0.377N
POLY 6	P=0.290N	(e)	P=0.415N	P=0.624N
COCH-ARM / FISHERS	P=0.133N	(e)	P=0.381N	P=0.345N
MAX-ISO-POLY-3	P=0.179N	(e)	P=0.122N	P=0.133N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose
Foreign Body**

LESION RATES

OVERALL (a)	11/50 (22%)	10/48 (21%)	15/48 (31%)	11/50 (22%)
POLY-3 RATE (b)	11/43.27	10/41.18	15/39.94	11/37.24
POLY-3 PERCENT (g)	25.4%	24.3%	37.6%	29.5%
TERMINAL (d)	5/23 (22%)	5/26 (19%)	7/18 (39%)	3/13 (23%)
FIRST INCIDENCE	501	505	418	611

STATISTICAL TESTS

POLY 3	P=0.280	P=0.552N	P=0.165	P=0.435
POLY 1.5	P=0.357	P=0.548N	P=0.184	P=0.502
POLY 6	P=0.198	P=0.553N	P=0.143	P=0.356
COCH-ARM / FISHERS	P=0.477	P=0.542N	P=0.210	P=0.595N
MAX-ISO-POLY-3	P=0.337	P=0.451N	P=0.118	P=0.348

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose
Inflammation Chronic**

LESION RATES

OVERALL (a)	29/50 (58%)	34/48 (71%)	36/48 (75%)	42/50 (84%)
POLY-3 RATE (b)	29/44.85	34/43.76	36/43.38	42/48.57
POLY-3 PERCENT (g)	64.7%	77.7%	83%	86.5%
TERMINAL (d)	16/23 (70%)	21/26 (81%)	16/18 (89%)	9/13 (69%)
FIRST INCIDENCE	501	505	418	394

STATISTICAL TESTS

POLY 3	P=0.006**	P=0.114	P=0.029*	P=0.008**
POLY 1.5	P=0.004**	P=0.121	P=0.040*	P=0.005**
POLY 6	P=0.013*	P=0.114	P=0.020*	P=0.017*
COCH-ARM / FISHERS	P=0.003**	P=0.132	P=0.058	P=0.004**
MAX-ISO-POLY-3	P=0.005**	P=0.072	P=0.016*	P=0.005**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	44/50 (88%)	39/48 (81%)	36/48 (75%)	44/50 (88%)
POLY-3 RATE (b)	44/48.40	39/45.97	36/44.55	44/48.65
POLY-3 PERCENT (g)	90.9%	84.8%	80.8%	90.4%
TERMINAL (d)	20/23 (87%)	22/26 (85%)	14/18 (78%)	12/13 (92%)
FIRST INCIDENCE	501	505	488	394

STATISTICAL TESTS

POLY 3	P=0.529	P=0.265N	P=0.116N	P=0.613N
POLY 1.5	P=0.526	P=0.255N	P=0.094N	P=0.606N
POLY 6	P=0.507	P=0.294N	P=0.162N	P=0.655N
COCH-ARM / FISHERS	P=0.504	P=0.259N	P=0.080N	P=0.620N
MAX-ISO-POLY-3	P=0.317N	P=0.172N	P=0.070N	P=0.465N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Glands
Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	14/48 (29%)	14/48 (29%)	15/50 (30%)
POLY-3 RATE (b)	5/42.60	14/40.59	14/38.15	15/39.83
POLY-3 PERCENT (g)	11.7%	34.5%	36.7%	37.7%
TERMINAL (d)	2/23 (9%)	8/26 (31%)	9/18 (50%)	5/13 (39%)
FIRST INCIDENCE	501	660	534	449

STATISTICAL TESTS

POLY 3	P=0.011*	P=0.011*	P=0.006**	P=0.005**
POLY 1.5	P=0.017*	P=0.012*	P=0.009**	P=0.006**
POLY 6	P=0.007**	P=0.010**	P=0.004**	P=0.003**
COCH-ARM / FISHERS	P=0.031*	P=0.015*	P=0.015*	P=0.011*
MAX-ISO-POLY-3	P=0.007**	P=0.006**	P=0.004**	P=0.003**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	7/50 (14%)	10/48 (21%)	12/48 (25%)	12/50 (24%)
POLY-3 RATE (b)	7/42.30	10/41.66	12/39.54	12/38.89
POLY-3 PERCENT (g)	16.6%	24%	30.4%	30.9%
TERMINAL (d)	3/23 (13%)	5/26 (19%)	5/18 (28%)	3/13 (23%)
FIRST INCIDENCE	586	505	418	484

STATISTICAL TESTS

POLY 3	P=0.080	P=0.280	P=0.108	P=0.100
POLY 1.5	P=0.102	P=0.274	P=0.118	P=0.119
POLY 6	P=0.059	P=0.294	P=0.097	P=0.081
COCH-ARM / FISHERS	P=0.144	P=0.266	P=0.131	P=0.154
MAX-ISO-POLY-3	P=0.120	P=0.197	P=0.071	P=0.068

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	14/50 (28%)	15/48 (31%)	20/48 (42%)	17/50 (34%)
POLY-3 RATE (b)	14/43.82	15/41.94	20/41.40	17/39.45
POLY-3 PERCENT (g)	32%	35.8%	48.3%	43.1%
TERMINAL (d)	6/23 (26%)	7/26 (27%)	8/18 (44%)	5/13 (39%)
FIRST INCIDENCE	501	505	418	484

STATISTICAL TESTS

POLY 3	P=0.127	P=0.442	P=0.087	P=0.200
POLY 1.5	P=0.175	P=0.444	P=0.097	P=0.250
POLY 6	P=0.082	P=0.444	P=0.077	P=0.148
COCH-ARM / FISHERS	P=0.266	P=0.448	P=0.113	P=0.333
MAX-ISO-POLY-3	P=0.170	P=0.353	P=0.059	P=0.153

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Respiratory Epithelium
Metaplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/48 (2%)	0/48 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/41.70	1/39.97	0/36.71	2/36.17
POLY-3 PERCENT (g)	2.4%	2.5%	0%	5.5%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	660	663	---	659

STATISTICAL TESTS

POLY 3	P=0.335	P=0.752	P=0.525N	P=0.450
POLY 1.5	P=0.350	P=0.751	P=0.518N	P=0.471
POLY 6	P=0.316	P=0.754	P=0.535N	P=0.424
COCH-ARM / FISHERS	P=0.370	P=0.742	P=0.510N	P=0.500
MAX-ISO-POLY-3	P=0.263	P=0.487	P=0.187N	P=0.254

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
Foreign Body**

LESION RATES

OVERALL (a)	1/3 (33%)	0/0 (0%)	1/2 (50%)	2/4 (50%)
POLY-3 RATE (b)	1/2.77	0/0.00	1/2.00	2/3.52
POLY-3 PERCENT (g)	36.1%	0%	50%	56.8%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	1/2 (50%)	1/1 (100%)
FIRST INCIDENCE	724	---	729 (T)	666

STATISTICAL TESTS

POLY 3	(e)	(e)	P=0.694	P=0.602
POLY 1.5	(e)	(e)	P=0.682	P=0.607
POLY 6	(e)	(e)	P=0.714	P=0.593
COCH-ARM / FISHERS	P=0.483	(e)	P=0.700	P=0.629
MAX-ISO-POLY-3	(e)	(e)	P=0.407	P=0.328

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
Hyperplasia**

LESION RATES

OVERALL (a)	1/3 (33%)	0/0 (0%)	1/2 (50%)	0/4 (0%)
POLY-3 RATE (b)	1/2.75	0/0.00	1/2.00	0/3.29
POLY-3 PERCENT (g)	36.3%	0%	50%	0%
TERMINAL (d)	1/1 (100%)	0/0 (0%)	1/2 (50%)	0/1 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---

STATISTICAL TESTS

POLY 3	(e)	(e)	P=0.696	P=0.463N
POLY 1.5	(e)	(e)	P=0.684	P=0.452N
POLY 6	(e)	(e)	P=0.719	P=0.484N
COCH-ARM / FISHERS	P=0.254N	(e)	P=0.700	P=0.429N
MAX-ISO-POLY-3	(e)	(e)	P=0.409	P=0.127N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/3 (33%)	0/0 (0%)	0/2 (0%)	2/4 (50%)
POLY-3 RATE (b)	1/2.77	0/0.00	0/2.00	2/3.52
POLY-3 PERCENT (g)	36.1%	0%	0%	56.8%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/2 (0%)	1/1 (100%)
FIRST INCIDENCE	724	---	---	666

STATISTICAL TESTS

POLY 3	(e)	(e)	P=0.564N	P=0.602
POLY 1.5	(e)	(e)	P=0.570N	P=0.607
POLY 6	(e)	(e)	P=0.552N	P=0.593
COCH-ARM / FISHERS	P=0.446	(e)	P=0.600N	P=0.629
MAX-ISO-POLY-3	(e)	(e)	P=0.217N	P=0.328

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Pancreas: Acinus Atrophy

LESION RATES

OVERALL (a)	23/50 (46%)	13/50 (26%)	20/50 (40%)	23/50 (46%)
POLY-3 RATE (b)	23/45.35	13/42.41	20/43.66	23/40.03
POLY-3 PERCENT (g)	50.7%	30.7%	45.8%	57.5%
TERMINAL (d)	10/23 (44%)	8/26 (31%)	7/18 (39%)	8/13 (62%)
FIRST INCIDENCE	501	560	418	453

STATISTICAL TESTS

POLY 3	P=0.145	P=0.040N*	P=0.399N	P=0.337
POLY 1.5	P=0.197	P=0.035N*	P=0.372N	P=0.437
POLY 6	P=0.097	P=0.050N*	P=0.442N	P=0.226
COCH-ARM / FISHERS	P=0.287	P=0.030N*	P=0.343N	P=0.579N
MAX-ISO-POLY-3	P=0.107	P=0.028N*	P=0.321N	P=0.271

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Parathyroid Gland
Hyperplasia**

LESION RATES

OVERALL (a)	2/46 (4%)	0/48 (0%)	0/47 (0%)	0/46 (0%)
POLY-3 RATE (b)	2/37.44	0/38.69	0/35.30	0/34.24
POLY-3 PERCENT (g)	5.3%	0%	0%	0%
TERMINAL (d)	2/19 (11%)	0/24 (0%)	0/16 (0%)	0/13 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.112N	P=0.229N	P=0.250N	P=0.257N
POLY 1.5	P=0.112N	P=0.230N	P=0.242N	P=0.248N
POLY 6	P=0.113N	P=0.226N	P=0.259N	P=0.268N
COCH-ARM / FISHERS	P=0.114N	P=0.237N	P=0.242N	P=0.247N
MAX-ISO-POLY-3	P=0.047N*	P=0.073N	P=0.089N	P=0.094N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Pituitary Gland
Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	1/41.74	2/40.73	1/37.74	0/35.06
POLY-3 PERCENT (g)	2.4%	4.9%	2.7%	0%
TERMINAL (d)	0/23 (0%)	1/26 (4%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	646	719	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.295N	P=0.491	P=0.738	P=0.535N
POLY 1.5	P=0.276N	P=0.494	P=0.748	P=0.522N
POLY 6	P=0.322N	P=0.491	P=0.724	P=0.552N
COCH-ARM / FISHERS	P=0.251N	P=0.500	P=0.753N	P=0.505N
MAX-ISO-POLY-3	P=0.290N	P=0.275	P=0.472	P=0.199N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Pituitary Gland Hemorrhage

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	5/50 (10%)	0/49 (0%)
POLY-3 RATE (b)	4/42.64	2/41.44	5/39.36	0/35.06
POLY-3 PERCENT (g)	9.4%	4.8%	12.7%	0%
TERMINAL (d)	1/23 (4%)	0/26 (0%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	582	505	488	---

STATISTICAL TESTS

POLY 3	P=0.149N	P=0.350N	P=0.450	P=0.088N
POLY 1.5	P=0.125N	P=0.346N	P=0.472	P=0.077N
POLY 6	P=0.187N	P=0.352N	P=0.422	P=0.107N
COCH-ARM / FISHERS	P=0.099N	P=0.339N	P=0.500	P=0.061N
MAX-ISO-POLY-3	P=0.109N	P=0.213N	P=0.322	P=0.043N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	8/50 (16%)	5/50 (10%)	11/50 (22%)	7/49 (14%)
POLY-3 RATE (b)	8/42.78	5/40.85	11/39.83	7/36.17
POLY-3 PERCENT (g)	18.7%	12.2%	27.6%	19.4%
TERMINAL (d)	5/23 (22%)	4/26 (15%)	6/18 (33%)	2/13 (15%)
FIRST INCIDENCE	429	687	520	642

STATISTICAL TESTS

POLY 3	P=0.354	P=0.303N	P=0.239	P=0.585
POLY 1.5	P=0.410	P=0.295N	P=0.267	P=0.592N
POLY 6	P=0.291	P=0.307N	P=0.207	P=0.531
COCH-ARM / FISHERS	P=0.495	P=0.277N	P=0.306	P=0.517N
MAX-ISO-POLY-3	P=0.319	P=0.212N	P=0.174	P=0.471

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Preputial Gland
Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/41.93	0/40.69	0/37.18	1/35.80
POLY-3 PERCENT (g)	7.2%	0%	0%	2.8%
TERMINAL (d)	1/23 (4%)	0/26 (0%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	660	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.247N	P=0.123N	P=0.141N	P=0.363N
POLY 1.5	P=0.247N	P=0.122N	P=0.133N	P=0.338N
POLY 6	P=0.249N	P=0.124N	P=0.153N	P=0.399N
COCH-ARM / FISHERS	P=0.248N	P=0.121N	P=0.125N	P=0.309N
MAX-ISO-POLY-3	P=0.082N	P=0.042N*	P=0.056N	P=0.212N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Preputial Gland
Inflammation Chronic**

LESION RATES

OVERALL (a)	30/50 (60%)	34/50 (68%)	31/49 (63%)	37/50 (74%)
POLY-3 RATE (b)	30/45.82	34/43.95	31/41.43	37/44.04
POLY-3 PERCENT (g)	65.5%	77.4%	74.8%	84%
TERMINAL (d)	15/23 (65%)	24/26 (92%)	16/18 (89%)	12/13 (92%)
FIRST INCIDENCE	582	505	514	453

STATISTICAL TESTS

POLY 3	P=0.025*	P=0.138	P=0.220	P=0.026*
POLY 1.5	P=0.049*	P=0.188	P=0.319	P=0.045*
POLY 6	P=0.011*	P=0.084	P=0.114	P=0.014*
COCH-ARM / FISHERS	P=0.109	P=0.266	P=0.449	P=0.101
MAX-ISO-POLY-3	P=0.019*	P=0.095	P=0.164	P=0.015*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Prostate
Hyperplasia**

LESION RATES

OVERALL (a)	12/50 (24%)	13/50 (26%)	10/50 (20%)	17/50 (34%)
POLY-3 RATE (b)	12/42.52	13/42.65	10/38.98	17/38.32
POLY-3 PERCENT (g)	28.2%	30.5%	25.7%	44.4%
TERMINAL (d)	8/23 (35%)	7/26 (27%)	5/18 (28%)	8/13 (62%)
FIRST INCIDENCE	596	569	603	422

STATISTICAL TESTS

POLY 3	P=0.078	P=0.504	P=0.495N	P=0.093
POLY 1.5	P=0.110	P=0.497	P=0.456N	P=0.129
POLY 6	P=0.047*	P=0.527	P=0.546N	P=0.057
COCH-ARM / FISHERS	P=0.163	P=0.500	P=0.405N	P=0.189
MAX-ISO-POLY-3	P=0.101	P=0.407	P=0.398N	P=0.068

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Prostate
Inflammation**

LESION RATES

OVERALL (a)	38/50 (76%)	42/50 (84%)	40/50 (80%)	36/50 (72%)
POLY-3 RATE (b)	38/46.21	42/47.70	40/45.55	36/44.26
POLY-3 PERCENT (g)	82.2%	88%	87.8%	81.3%
TERMINAL (d)	20/23 (87%)	22/26 (85%)	16/18 (89%)	11/13 (85%)
FIRST INCIDENCE	534	505	514	394

STATISTICAL TESTS

POLY 3	P=0.429N	P=0.293	P=0.303	P=0.572N
POLY 1.5	P=0.333N	P=0.247	P=0.342	P=0.496N
POLY 6	P=0.562	P=0.397	P=0.281	P=0.608
COCH-ARM / FISHERS	P=0.244N	P=0.227	P=0.405	P=0.410N
MAX-ISO-POLY-3	P=0.400N	P=0.199	P=0.201	P=0.450N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Salivary Glands
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	0/41.44	1/41.36	3/38.44	2/37.06
POLY-3 PERCENT (g)	0%	2.4%	7.8%	5.4%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	---	505	603	449

STATISTICAL TESTS

POLY 3	P=0.125	P=0.500	P=0.105	P=0.213
POLY 1.5	P=0.140	P=0.499	P=0.111	P=0.223
POLY 6	P=0.106	P=0.502	P=0.098	P=0.200
COCH-ARM / FISHERS	P=0.163	P=0.500	P=0.121	P=0.247
MAX-ISO-POLY-3	P=0.116	P=0.158	P=0.037*	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Seminal Vesicle
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	1/49 (2%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/41.80	1/40.13	0/36.86	2/35.98
POLY-3 PERCENT (g)	4.8%	2.5%	0%	5.6%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	635	711	---	682

STATISTICAL TESTS

POLY 3	P=0.555	P=0.514N	P=0.266N	P=0.639
POLY 1.5	P=0.571	P=0.513N	P=0.255N	P=0.663
POLY 6	P=0.533	P=0.513N	P=0.280N	P=0.608
COCH-ARM / FISHERS	P=0.592	P=0.508N	P=0.253N	P=0.691N
MAX-ISO-POLY-3	P=0.393	P=0.295N	P=0.102N	P=0.442

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Skin
Hyperkeratosis**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/41.70	0/40.69	2/38.01	0/35.80
POLY-3 PERCENT (g)	7.2%	0%	5.3%	0%
TERMINAL (d)	2/23 (9%)	0/26 (0%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	660	---	658	---

STATISTICAL TESTS

POLY 3	P=0.145N	P=0.122N	P=0.542N	P=0.148N
POLY 1.5	P=0.135N	P=0.122N	P=0.524N	P=0.135N
POLY 6	P=0.158N	P=0.122N	P=0.566N	P=0.166N
COCH-ARM / FISHERS	P=0.125N	P=0.121N	P=0.500N	P=0.121N
MAX-ISO-POLY-3	P=0.074N	P=0.041N*	P=0.367N	P=0.063N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	4/50 (8%)	5/50 (10%)	14/50 (28%)
POLY-3 RATE (b)	1/41.44	4/41.17	5/39.66	14/41.01
POLY-3 PERCENT (g)	2.4%	9.7%	12.6%	34.1%
TERMINAL (d)	1/23 (4%)	2/26 (8%)	2/18 (11%)	1/13 (8%)
FIRST INCIDENCE	729 (T)	611	418	422

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.175	P=0.090	P<0.001**
POLY 1.5	P<0.001**	P=0.176	P=0.095	P<0.001**
POLY 6	P<0.001**	P=0.179	P=0.083	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.181	P=0.102	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.082	P=0.041*	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Fibrosis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/41.44	2/40.69	1/37.29	0/35.80
POLY-3 PERCENT (g)	2.4%	4.9%	2.7%	0%
TERMINAL (d)	1/23 (4%)	2/26 (8%)	1/18 (6%)	0/13 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.289N	P=0.494	P=0.737	P=0.529N
POLY 1.5	P=0.272N	P=0.495	P=0.745	P=0.517N
POLY 6	P=0.313N	P=0.495	P=0.726	P=0.545N
COCH-ARM / FISHERS	P=0.248N	P=0.500	P=0.747	P=0.500N
MAX-ISO-POLY-3	P=0.284N	P=0.276	P=0.470	P=0.193N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	10/50 (20%)	17/50 (34%)	13/49 (27%)	6/50 (12%)
POLY-3 RATE (b)	10/42.00	17/41.26	13/37.99	6/36.17
POLY-3 PERCENT (g)	23.8%	41.2%	34.2%	16.6%
TERMINAL (d)	7/23 (30%)	15/26 (58%)	8/18 (44%)	4/13 (31%)
FIRST INCIDENCE	660	585	682	659

STATISTICAL TESTS

POLY 3	P=0.169N	P=0.066	P=0.213	P=0.305N
POLY 1.5	P=0.122N	P=0.073	P=0.249	P=0.260N
POLY 6	P=0.251N	P=0.060	P=0.173	P=0.370N
COCH-ARM / FISHERS	P=0.079N	P=0.088	P=0.298	P=0.207N
MAX-ISO-POLY-3	P=0.100N	P=0.041*	P=0.158	P=0.230N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Hemorrhage Chronic**

LESION RATES

OVERALL (a)	4/50 (8%)	0/50 (0%)	1/49 (2%)	3/50 (6%)
POLY-3 RATE (b)	4/42.73	0/40.69	1/37.37	3/36.53
POLY-3 PERCENT (g)	9.4%	0%	2.7%	8.2%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	591	---	709	639

STATISTICAL TESTS

POLY 3	P=0.561	P=0.066N	P=0.221N	P=0.585N
POLY 1.5	P=0.576	P=0.064N	P=0.205N	P=0.550N
POLY 6	P=0.539	P=0.068N	P=0.245N	P=0.631N
COCH-ARM / FISHERS	P=0.595	P=0.059N	P=0.187N	P=0.500N
MAX-ISO-POLY-3	P=0.216N	P=0.024N*	P=0.123N	P=0.432N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Infarct Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/49 (4%)	3/50 (6%)
POLY-3 RATE (b)	0/41.44	1/41.23	2/37.37	3/36.24
POLY-3 PERCENT (g)	0%	2.4%	5.4%	8.3%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	1/18 (6%)	1/13 (8%)
FIRST INCIDENCE	---	562	709	639

STATISTICAL TESTS

POLY 3	P=0.043*	P=0.499	P=0.214	P=0.096
POLY 1.5	P=0.051	P=0.499	P=0.222	P=0.105
POLY 6	P=0.036*	P=0.502	P=0.204	P=0.085
COCH-ARM / FISHERS	P=0.062	P=0.500	P=0.242	P=0.121
MAX-ISO-POLY-3	P=0.060	P=0.158	P=0.074	P=0.037*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Inflammation Granulomatous**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/41.44	0/40.69	0/37.29	0/35.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/41.91	1/41.23	1/37.87	1/36.08
POLY-3 PERCENT (g)	2.4%	2.4%	2.6%	2.8%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	591	562	697	653

STATISTICAL TESTS

POLY 3	P=0.579	P=0.757	P=0.738	P=0.727
POLY 1.5	P=0.602	P=0.758	P=0.748	P=0.741
POLY 6	P=0.548	P=0.759	P=0.725	P=0.707
COCH-ARM / FISHERS	P=0.634	P=0.753N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.702	P=0.495	P=0.471	P=0.460

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	7/50 (14%)	3/50 (6%)	5/50 (10%)	4/50 (8%)
POLY-3 RATE (b)	7/43.36	3/41.95	5/39.06	4/37.18
POLY-3 PERCENT (g)	16.1%	7.2%	12.8%	10.8%
TERMINAL (d)	1/23 (4%)	0/26 (0%)	0/18 (0%)	1/13 (8%)
FIRST INCIDENCE	582	585	603	446

STATISTICAL TESTS

POLY 3	P=0.379N	P=0.169N	P=0.454N	P=0.354N
POLY 1.5	P=0.343N	P=0.166N	P=0.421N	P=0.313N
POLY 6	P=0.433N	P=0.171N	P=0.496N	P=0.415N
COCH-ARM / FISHERS	P=0.298N	P=0.159N	P=0.380N	P=0.262N
MAX-ISO-POLY-3	P=0.357N	P=0.101N	P=0.341N	P=0.258N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Glandular
Ulcer**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/41.74	2/41.58	1/37.87	0/35.80
POLY-3 PERCENT (g)	2.4%	4.8%	2.6%	0%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	646	585	697	---

STATISTICAL TESTS

POLY 3	P=0.291N	P=0.499	P=0.739	P=0.531N
POLY 1.5	P=0.272N	P=0.498	P=0.748	P=0.518N
POLY 6	P=0.318N	P=0.504	P=0.726	P=0.548N
COCH-ARM / FISHERS	P=0.247N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.289N	P=0.279	P=0.472	P=0.196N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Testes: Germinal Epithelium Atrophy

LESION RATES

OVERALL (a)	12/50 (24%)	8/50 (16%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	12/42.59	8/40.73	7/38.71	6/36.39
POLY-3 PERCENT (g)	28.2%	19.6%	18.1%	16.5%
TERMINAL (d)	7/23 (30%)	7/26 (27%)	5/18 (28%)	4/13 (31%)
FIRST INCIDENCE	646	719	488	639

STATISTICAL TESTS

POLY 3	P=0.134N	P=0.254N	P=0.206N	P=0.165N
POLY 1.5	P=0.110N	P=0.244N	P=0.181N	P=0.131N
POLY 6	P=0.177N	P=0.266N	P=0.248N	P=0.219N
COCH-ARM / FISHERS	P=0.083N	P=0.227N	P=0.154N	P=0.096N
MAX-ISO-POLY-3	P=0.185N	P=0.184N	P=0.149N	P=0.123N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Testes: Interstitial Cell
Hyperplasia

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/41.92	0/40.69	2/38.89	1/36.08
POLY-3 PERCENT (g)	2.4%	0%	5.1%	2.8%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	586	---	536	653

STATISTICAL TESTS

POLY 3	P=0.440	P=0.506N	P=0.474	P=0.727
POLY 1.5	P=0.465	P=0.504N	P=0.485	P=0.741
POLY 6	P=0.406	P=0.507N	P=0.459	P=0.707
COCH-ARM / FISHERS	P=0.500	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.382	P=0.166N	P=0.265	P=0.459

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Thyroid Gland: C-Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	32/50 (64%)	31/50 (62%)	29/50 (58%)	34/49 (69%)
POLY-3 RATE (b)	32/46.15	31/43.77	29/41.73	34/42.99
POLY-3 PERCENT (g)	69.3%	70.8%	69.5%	79.1%
TERMINAL (d)	15/23 (65%)	21/26 (81%)	14/18 (78%)	10/13 (77%)
FIRST INCIDENCE	534	540	536	422

STATISTICAL TESTS

POLY 3	P=0.156	P=0.532	P=0.591	P=0.193
POLY 1.5	P=0.216	P=0.589	P=0.481N	P=0.256
POLY 6	P=0.104	P=0.450	P=0.438	P=0.138
COCH-ARM / FISHERS	P=0.312	P=0.500N	P=0.341N	P=0.361
MAX-ISO-POLY-3	P=0.219	P=0.435	P=0.492	P=0.136

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

Thyroid Gland: Follicular Cell Hyperplasia

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/41.44	1/40.77	0/37.74	0/35.42
POLY-3 PERCENT (g)	0%	2.5%	0%	0%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	---	708	---	---

STATISTICAL TESTS

POLY 3	P=0.585N	P=0.497	(e)	(e)
POLY 1.5	P=0.579N	P=0.497	(e)	(e)
POLY 6	P=0.593N	P=0.498	(e)	(e)
COCH-ARM / FISHERS	P=0.571N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.433N	P=0.158	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Trachea
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/41.70	1/40.76	1/37.89	4/38.63
POLY-3 PERCENT (g)	2.4%	2.5%	2.6%	10.4%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	660	711	690	394

STATISTICAL TESTS

POLY 3	P=0.057	P=0.756	P=0.739	P=0.155
POLY 1.5	P=0.062	P=0.757	P=0.749	P=0.165
POLY 6	P=0.051	P=0.757	P=0.727	P=0.140
COCH-ARM / FISHERS	P=0.067	P=0.753N	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.071	P=0.493	P=0.473	P=0.077

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	125 PPM	250 PPM	500 PPM

**Trachea: Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/41.70	0/40.69	0/37.74	1/36.34
POLY-3 PERCENT (g)	2.4%	0%	0%	2.8%
TERMINAL (d)	0/23 (0%)	0/26 (0%)	0/18 (0%)	0/13 (0%)
FIRST INCIDENCE	660	---	---	562

STATISTICAL TESTS

POLY 3	P=0.575	P=0.505N	P=0.520N	P=0.730
POLY 1.5	P=0.583	P=0.503N	P=0.511N	P=0.743
POLY 6	P=0.562	P=0.505N	P=0.532N	P=0.711
COCH-ARM / FISHERS	P=0.595	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.391	P=0.164N	P=0.182N	P=0.463

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	27/50 (54%)	30/50 (60%)	24/50 (48%)	26/50 (52%)
POLY-3 RATE (b)	27/47.14	30/45.27	24/43.49	26/40.20
POLY-3 PERCENT (g)	57.3%	66.3%	55.2%	64.7%
TERMINAL (d)	22/34 (65%)	24/33 (73%)	20/30 (67%)	18/24 (75%)
FIRST INCIDENCE	493	577	607	450

STATISTICAL TESTS

POLY 3	P=0.374	P=0.243	P=0.505N	P=0.308
POLY 1.5	P=0.492	P=0.282	P=0.436N	P=0.418
POLY 6	P=0.255	P=0.208	P=0.589	P=0.206
COCH-ARM / FISHERS	P=0.342N	P=0.343	P=0.345N	P=0.500N
MAX-ISO-POLY-3	P=0.402	P=0.185	P=0.420N	P=0.250

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Cortex
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	12/50 (24%)	16/50 (32%)	16/50 (32%)	11/50 (22%)
POLY-3 RATE (b)	12/45.61	16/43.86	16/43.81	11/39.02
POLY-3 PERCENT (g)	26.3%	36.5%	36.5%	28.2%
TERMINAL (d)	10/34 (29%)	15/33 (46%)	11/30 (37%)	8/24 (33%)
FIRST INCIDENCE	683	708	607	578

STATISTICAL TESTS

POLY 3	P=0.505	P=0.207	P=0.206	P=0.520
POLY 1.5	P=0.512N	P=0.226	P=0.224	P=0.571
POLY 6	P=0.439	P=0.186	P=0.191	P=0.468
COCH-ARM / FISHERS	P=0.364N	P=0.252	P=0.252	P=0.500N
MAX-ISO-POLY-3	P=0.393	P=0.152	P=0.151	P=0.427

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	9/50 (18%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	4/45.31	9/44.38	7/43.21	6/38.22
POLY-3 PERCENT (g)	8.8%	20.3%	16.2%	15.7%
TERMINAL (d)	4/34 (12%)	6/33 (18%)	5/30 (17%)	4/24 (17%)
FIRST INCIDENCE	730 (T)	575	541	611

STATISTICAL TESTS

POLY 3	P=0.314	P=0.106	P=0.233	P=0.267
POLY 1.5	P=0.361	P=0.110	P=0.245	P=0.298
POLY 6	P=0.269	P=0.103	P=0.220	P=0.238
COCH-ARM / FISHERS	P=0.472	P=0.117	P=0.262	P=0.370
MAX-ISO-POLY-3	P=0.256	P=0.062	P=0.152	P=0.188

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Bone
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	1/37.64
POLY-3 PERCENT (g)	0%	0%	0%	2.7%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	---	---	730 (T)

STATISTICAL TESTS

POLY 3	P=0.177	(e)	(e)	P=0.463
POLY 1.5	P=0.184	(e)	(e)	P=0.475
POLY 6	P=0.171	(e)	(e)	P=0.450
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Brain
Hemorrhage**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/45.31	0/43.77	1/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	---	---	730 (T)	---

STATISTICAL TESTS

POLY 3	P=0.616	(e)	P=0.487	(e)
POLY 1.5	P=0.642	(e)	P=0.492	(e)
POLY 6	P=0.588	(e)	P=0.481	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.408	(e)	P=0.158	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Clitoral Gland
Hyperplasia**

LESION RATES

OVERALL (a)	3/49 (6%)	5/50 (10%)	9/49 (18%)	4/49 (8%)
POLY-3 RATE (b)	3/44.31	5/44.60	9/43.07	4/38.20
POLY-3 PERCENT (g)	6.8%	11.2%	20.9%	10.5%
TERMINAL (d)	3/33 (9%)	2/33 (6%)	4/30 (13%)	1/24 (4%)
FIRST INCIDENCE	730 (T)	603	607	529

STATISTICAL TESTS

POLY 3	P=0.280	P=0.360	P=0.052	P=0.419
POLY 1.5	P=0.317	P=0.362	P=0.054	P=0.443
POLY 6	P=0.246	P=0.360	P=0.050*	P=0.398
COCH-ARM / FISHERS	P=0.418	P=0.369	P=0.060	P=0.500
MAX-ISO-POLY-3	P=0.193	P=0.234	P=0.027*	P=0.290

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Clitoral Gland
Inflammation Chronic**

LESION RATES

OVERALL (a)	22/49 (45%)	26/50 (52%)	26/49 (53%)	18/49 (37%)
POLY-3 RATE (b)	22/44.43	26/44.20	26/42.20	18/38.28
POLY-3 PERCENT (g)	49.5%	58.8%	61.6%	47%
TERMINAL (d)	21/33 (64%)	22/33 (67%)	22/30 (73%)	16/24 (67%)
FIRST INCIDENCE	701	687	680	142

STATISTICAL TESTS

POLY 3	P=0.428N	P=0.246	P=0.170	P=0.498N
POLY 1.5	P=0.326N	P=0.270	P=0.210	P=0.411N
POLY 6	P=0.527	P=0.226	P=0.133	P=0.589
COCH-ARM / FISHERS	P=0.175N	P=0.307	P=0.272	P=0.269N
MAX-ISO-POLY-3	P=0.326N	P=0.184	P=0.126	P=0.412N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Coagulating Gland
Inflammation**

LESION RATES

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Eye
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Eye: Lens
Cataract

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	4/45.62	3/44.20	5/42.84	2/37.64
POLY-3 PERCENT (g)	8.8%	6.8%	11.7%	5.3%
TERMINAL (d)	3/34 (9%)	2/33 (6%)	4/30 (13%)	2/24 (8%)
FIRST INCIDENCE	647	603	628	730 (T)

STATISTICAL TESTS

POLY 3	P=0.430N	P=0.517N	P=0.461	P=0.429N
POLY 1.5	P=0.393N	P=0.510N	P=0.477	P=0.398N
POLY 6	P=0.472N	P=0.524N	P=0.441	P=0.465N
COCH-ARM / FISHERS	P=0.320N	P=0.500N	P=0.500	P=0.339N
MAX-ISO-POLY-3	P=0.466N	P=0.365N	P=0.331	P=0.292N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Harderian Gland
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/45.31	0/43.77	1/42.47	2/38.03
POLY-3 PERCENT (g)	0%	0%	2.4%	5.3%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	1/30 (3%)	1/24 (4%)
FIRST INCIDENCE	---	---	730 (T)	619

STATISTICAL TESTS

POLY 3	P=0.054	(e)	P=0.487	P=0.200
POLY 1.5	P=0.058	(e)	P=0.492	P=0.212
POLY 6	P=0.049*	(e)	P=0.481	P=0.189
COCH-ARM / FISHERS	P=0.070	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.077	(e)	P=0.158	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	35/50 (70%)	32/50 (64%)	34/50 (68%)	21/50 (42%)
POLY-3 RATE (b)	35/46.22	32/44.00	34/44.33	21/38.10
POLY-3 PERCENT (g)	75.7%	72.7%	76.7%	55.1%
TERMINAL (d)	30/34 (88%)	29/33 (88%)	26/30 (87%)	19/24 (79%)
FIRST INCIDENCE	633	697	451	611

STATISTICAL TESTS

POLY 3	P=0.024N*	P=0.464N	P=0.559	P=0.028N*
POLY 1.5	P=0.012N*	P=0.402N	P=0.582N	P=0.014N*
POLY 6	P=0.055N	P=0.557N	P=0.491	P=0.061N
COCH-ARM / FISHERS	P=0.003N**	P=0.335N	P=0.500N	P=0.004N**
MAX-ISO-POLY-3	P=0.031N*	P=0.365N	P=0.452	P=0.024N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Heart: Atrium
Thrombosis

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/45.37	0/43.77	0/42.47	0/37.64
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	716	---	---	---

STATISTICAL TESTS

POLY 3	P=0.285N	P=0.507N	P=0.513N	P=0.537N
POLY 1.5	P=0.292N	P=0.504N	P=0.508N	P=0.525N
POLY 6	P=0.278N	P=0.510N	P=0.520N	P=0.550N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.192N	P=0.168N	P=0.175N	P=0.204N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	0/45.31	3/43.77	4/43.40	4/37.64
POLY-3 PERCENT (g)	0%	6.9%	9.2%	10.6%
TERMINAL (d)	0/34 (0%)	3/33 (9%)	2/30 (7%)	4/24 (17%)
FIRST INCIDENCE	---	730 (T)	554	730 (T)

STATISTICAL TESTS

POLY 3	P=0.041*	P=0.112	P=0.055	P=0.040*
POLY 1.5	P=0.051	P=0.115	P=0.057	P=0.046*
POLY 6	P=0.032*	P=0.110	P=0.052	P=0.034*
COCH-ARM / FISHERS	P=0.078	P=0.121	P=0.059	P=0.059
MAX-ISO-POLY-3	P=0.059	P=0.038*	P=0.019*	P=0.018*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Islets, Pancreatic
Metaplasia Hepatocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/45.31	0/43.77	2/42.87	1/37.82
POLY-3 PERCENT (g)	0%	0%	4.7%	2.6%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	---	---	618	682

STATISTICAL TESTS

POLY 3	P=0.184	(e)	P=0.225	P=0.464
POLY 1.5	P=0.202	(e)	P=0.230	P=0.476
POLY 6	P=0.166	(e)	P=0.219	P=0.452
COCH-ARM / FISHERS	P=0.246	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.197	(e)	P=0.076	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney
Nephropathy Chronic**

LESION RATES

OVERALL (a)	35/49 (71%)	35/50 (70%)	31/50 (62%)	29/50 (58%)
POLY-3 RATE (b)	35/46.95	35/47.84	31/44.95	29/40.35
POLY-3 PERCENT (g)	74.5%	73.2%	69%	71.9%
TERMINAL (d)	26/34 (77%)	24/33 (73%)	22/30 (73%)	19/24 (79%)
FIRST INCIDENCE	493	433	541	450

STATISTICAL TESTS

POLY 3	P=0.395N	P=0.533N	P=0.353N	P=0.484N
POLY 1.5	P=0.250N	P=0.527N	P=0.291N	P=0.328N
POLY 6	P=0.507	P=0.543N	P=0.437N	P=0.544
COCH-ARM / FISHERS	P=0.070N	P=0.526N	P=0.217N	P=0.117N
MAX-ISO-POLY-3	P=0.536N	P=0.436N	P=0.274N	P=0.390N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney: Cortex, Renal Tubule
Casts Granular**

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.45	0/43.77	0/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Kidney: Pelvis
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.45	0/43.77	1/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	---	---	730 (T)	---

STATISTICAL TESTS

POLY 3	P=0.619	(e)	P=0.491	(e)
POLY 1.5	P=0.644	(e)	P=0.496	(e)
POLY 6	P=0.590	(e)	P=0.484	(e)
COCH-ARM / FISHERS	P=0.697	(e)	P=0.505	(e)
MAX-ISO-POLY-3	P=0.409	(e)	P=0.160	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Larynx
Foreign Body

LESION RATES

OVERALL (a)	8/50 (16%)	6/50 (12%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	8/46.48	6/43.82	3/42.47	4/38.37
POLY-3 PERCENT (g)	17.2%	13.7%	7.1%	10.4%
TERMINAL (d)	5/34 (15%)	5/33 (15%)	3/30 (10%)	2/24 (8%)
FIRST INCIDENCE	493	716	730 (T)	498

STATISTICAL TESTS

POLY 3	P=0.168N	P=0.432N	P=0.128N	P=0.283N
POLY 1.5	P=0.149N	P=0.414N	P=0.116N	P=0.245N
POLY 6	P=0.194N	P=0.453N	P=0.146N	P=0.328N
COCH-ARM / FISHERS	P=0.113N	P=0.387N	P=0.100N	P=0.178N
MAX-ISO-POLY-3	P=0.224N	P=0.327N	P=0.081N	P=0.209N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Larynx
Inflammation Chronic**

LESION RATES

OVERALL (a)	18/50 (36%)	25/50 (50%)	30/50 (60%)	35/50 (70%)
POLY-3 RATE (b)	18/46.35	25/45.82	30/44.92	35/45.48
POLY-3 PERCENT (g)	38.8%	54.6%	66.8%	77%
TERMINAL (d)	15/34 (44%)	18/33 (55%)	22/30 (73%)	17/24 (71%)
FIRST INCIDENCE	493	433	541	386

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.091	P=0.005**	P<0.001**
POLY 1.5	P<0.001**	P=0.099	P=0.007**	P<0.001**
POLY 6	P<0.001**	P=0.084	P=0.003**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.113	P=0.014*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.062	P=0.003**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Larynx
Metaplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	6/50 (12%)	21/50 (42%)
POLY-3 RATE (b)	3/46.15	2/43.90	6/42.80	21/42.71
POLY-3 PERCENT (g)	6.5%	4.6%	14%	49.2%
TERMINAL (d)	1/34 (3%)	1/33 (3%)	4/30 (13%)	8/24 (33%)
FIRST INCIDENCE	493	697	688	431

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.523N	P=0.206	P<0.001**
POLY 1.5	P<0.001**	P=0.514N	P=0.220	P<0.001**
POLY 6	P<0.001**	P=0.532N	P=0.190	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.243	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.347N	P=0.129	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Angiectasis**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/45.31	2/43.77	2/42.64	1/37.64
POLY-3 PERCENT (g)	6.6%	4.6%	4.7%	2.7%
TERMINAL (d)	3/34 (9%)	2/33 (6%)	1/30 (3%)	1/24 (4%)
FIRST INCIDENCE	730 (T)	730 (T)	688	730 (T)

STATISTICAL TESTS

POLY 3	P=0.286N	P=0.516N	P=0.528N	P=0.374N
POLY 1.5	P=0.269N	P=0.509N	P=0.516N	P=0.351N
POLY 6	P=0.305N	P=0.522N	P=0.541N	P=0.400N
COCH-ARM / FISHERS	P=0.232N	P=0.500N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.362N	P=0.340N	P=0.352N	P=0.224N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	40/50 (80%)	43/50 (86%)	42/50 (84%)	39/50 (78%)
POLY-3 RATE (b)	40/47.89	43/46.52	42/45.78	39/44.04
POLY-3 PERCENT (g)	83.5%	92.4%	91.8%	88.6%
TERMINAL (d)	30/34 (88%)	32/33 (97%)	30/30 (100%)	21/24 (88%)
FIRST INCIDENCE	438	575	534	453

STATISTICAL TESTS

POLY 3	P=0.322	P=0.130	P=0.157	P=0.336
POLY 1.5	P=0.419	P=0.188	P=0.249	P=0.411
POLY 6	P=0.274	P=0.087	P=0.076	P=0.310
COCH-ARM / FISHERS	P=0.354N	P=0.298	P=0.398	P=0.500N
MAX-ISO-POLY-3	P=0.168	P=0.072	P=0.091	P=0.236

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
 Clear Cell Focus

LESION RATES

OVERALL (a)	30/50 (60%)	34/50 (68%)	35/50 (70%)	35/50 (70%)
POLY-3 RATE (b)	30/47.28	34/46.16	35/45.29	35/43.47
POLY-3 PERCENT (g)	63.5%	73.7%	77.3%	80.5%
TERMINAL (d)	21/34 (62%)	26/33 (79%)	24/30 (80%)	20/24 (83%)
FIRST INCIDENCE	633	433	554	386

STATISTICAL TESTS

POLY 3	P=0.038*	P=0.193	P=0.100	P=0.050*
POLY 1.5	P=0.064	P=0.226	P=0.135	P=0.076
POLY 6	P=0.022*	P=0.151	P=0.070	P=0.031*
COCH-ARM / FISHERS	P=0.194	P=0.266	P=0.201	P=0.201
MAX-ISO-POLY-3	P=0.048*	P=0.139	P=0.069	P=0.034*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Degeneration Cystic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	1/37.64
POLY-3 PERCENT (g)	0%	0%	0%	2.7%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	---	---	730 (T)

STATISTICAL TESTS

POLY 3	P=0.177	(e)	(e)	P=0.463
POLY 1.5	P=0.184	(e)	(e)	P=0.475
POLY 6	P=0.171	(e)	(e)	P=0.450
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Liver
 Hepatodiaphragmatic Nodule

LESION RATES

OVERALL (a)	4/50 (8%)	9/50 (18%)	5/50 (10%)	5/50 (10%)
POLY-3 RATE (b)	4/45.31	9/43.90	5/43.36	5/38.82
POLY-3 PERCENT (g)	8.8%	20.5%	11.5%	12.9%
TERMINAL (d)	4/34 (12%)	8/33 (24%)	2/30 (7%)	3/24 (13%)
FIRST INCIDENCE	730 (T)	697	547	450

STATISTICAL TESTS

POLY 3	P=0.504	P=0.102	P=0.472	P=0.404
POLY 1.5	P=0.544	P=0.107	P=0.483	P=0.433
POLY 6	P=0.461	P=0.096	P=0.461	P=0.373
COCH-ARM / FISHERS	P=0.485N	P=0.117	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.357	P=0.060	P=0.340	P=0.291

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	2/45.31	2/44.03	3/43.26	3/38.38
POLY-3 PERCENT (g)	4.4%	4.5%	6.9%	7.8%
TERMINAL (d)	2/34 (6%)	1/33 (3%)	1/30 (3%)	1/24 (4%)
FIRST INCIDENCE	730 (T)	659	607	626

STATISTICAL TESTS

POLY 3	P=0.292	P=0.684	P=0.479	P=0.425
POLY 1.5	P=0.315	P=0.687	P=0.487	P=0.448
POLY 6	P=0.270	P=0.681	P=0.470	P=0.402
COCH-ARM / FISHERS	P=0.371	P=0.691N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.442	P=0.488	P=0.309	P=0.275

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	CONTROL	Females		
		125 PPM	250 PPM	500 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/45.31	0/43.77	1/43.05	0/37.64
POLY-3 PERCENT (g)	2.2%	0%	2.3%	0%
TERMINAL (d)	1/34 (3%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	730 (T)	---	547	---

STATISTICAL TESTS

POLY 3	P=0.429N	P=0.507N	P=0.749	P=0.537N
POLY 1.5	P=0.422N	P=0.504N	P=0.754	P=0.525N
POLY 6	P=0.436N	P=0.510N	P=0.744	P=0.550N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.328N	P=0.167N	P=0.485	P=0.203N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Liver
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	40/50 (80%)	41/50 (82%)	39/50 (78%)	47/50 (94%)
POLY-3 RATE (b)	40/47.44	41/47.14	39/45.93	47/47.85
POLY-3 PERCENT (g)	84.3%	87%	84.9%	98.2%
TERMINAL (d)	29/34 (85%)	30/33 (91%)	27/30 (90%)	24/24 (100%)
FIRST INCIDENCE	633	433	547	386

STATISTICAL TESTS

POLY 3	P=0.012*	P=0.468	P=0.589	P=0.012*
POLY 1.5	P=0.011*	P=0.486	P=0.587N	P=0.009**
POLY 6	P=0.017*	P=0.441	P=0.525	P=0.020*
COCH-ARM / FISHERS	P=0.038*	P=0.500	P=0.500N	P=0.036*
MAX-ISO-POLY-3	P=0.013*	P=0.346	P=0.466	P=0.004**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung
Hemorrhage**

LESION RATES

OVERALL (a)	4/50 (8%)	6/50 (12%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	4/45.31	6/43.77	4/42.66	4/37.82
POLY-3 PERCENT (g)	8.8%	13.7%	9.4%	10.6%
TERMINAL (d)	4/34 (12%)	6/33 (18%)	3/30 (10%)	3/24 (13%)
FIRST INCIDENCE	730 (T)	730 (T)	681	682

STATISTICAL TESTS

POLY 3	P=0.540	P=0.347	P=0.610	P=0.541
POLY 1.5	P=0.545N	P=0.357	P=0.623	P=0.574
POLY 6	P=0.497	P=0.338	P=0.595	P=0.505
COCH-ARM / FISHERS	P=0.467N	P=0.370	P=0.643N	P=0.643N
MAX-ISO-POLY-3	P=0.585	P=0.238	P=0.465	P=0.401

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	6/50 (12%)	10/50 (20%)	12/50 (24%)	6/50 (12%)
POLY-3 RATE (b)	6/45.31	10/44.30	12/42.89	6/39.91
POLY-3 PERCENT (g)	13.2%	22.6%	28%	15%
TERMINAL (d)	6/34 (18%)	7/33 (21%)	9/30 (30%)	2/24 (8%)
FIRST INCIDENCE	730 (T)	632	680	431

STATISTICAL TESTS

POLY 3	P=0.473	P=0.189	P=0.071	P=0.529
POLY 1.5	P=0.517	P=0.196	P=0.080	P=0.555
POLY 6	P=0.429	P=0.185	P=0.061	P=0.504
COCH-ARM / FISHERS	P=0.475N	P=0.207	P=0.096	P=0.620N
MAX-ISO-POLY-3	P=0.273	P=0.127	P=0.045*	P=0.410

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	11/50 (22%)	10/50 (20%)	16/50 (32%)	8/50 (16%)
POLY-3 RATE (b)	11/45.37	10/43.77	16/44.70	8/37.99
POLY-3 PERCENT (g)	24.3%	22.9%	35.8%	21.1%
TERMINAL (d)	10/34 (29%)	10/33 (30%)	9/30 (30%)	6/24 (25%)
FIRST INCIDENCE	716	730 (T)	541	682

STATISTICAL TESTS

POLY 3	P=0.540	P=0.538N	P=0.165	P=0.467N
POLY 1.5	P=0.478N	P=0.522N	P=0.171	P=0.413N
POLY 6	P=0.470	P=0.554N	P=0.163	P=0.524N
COCH-ARM / FISHERS	P=0.334N	P=0.500N	P=0.184	P=0.306N
MAX-ISO-POLY-3	P=0.430N	P=0.437N	P=0.115	P=0.374N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	30/50 (60%)	30/50 (60%)	29/50 (58%)	26/50 (52%)
POLY-3 RATE (b)	30/46.91	30/45.87	29/44.71	26/39.58
POLY-3 PERCENT (g)	64%	65.4%	64.9%	65.7%
TERMINAL (d)	24/34 (71%)	24/33 (73%)	21/30 (70%)	18/24 (75%)
FIRST INCIDENCE	438	433	541	590

STATISTICAL TESTS

POLY 3	P=0.481	P=0.529	P=0.552	P=0.523
POLY 1.5	P=0.469N	P=0.552	P=0.578N	P=0.531N
POLY 6	P=0.361	P=0.500	P=0.516	P=0.402
COCH-ARM / FISHERS	P=0.212N	P=0.581N	P=0.500N	P=0.273N
MAX-ISO-POLY-3	P=0.671	P=0.439	P=0.462	P=0.433

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Bronchial
Angiectasis**

LESION RATES

OVERALL (a)	1/1 (100%)	0/4 (0%)	2/5 (40%)	1/7 (14%)
POLY-3 RATE (b)	1/1.00	0/2.78	2/4.40	1/5.59
POLY-3 PERCENT (g)	100%	0%	45.5%	17.9%
TERMINAL (d)	0/0 (0%)	0/1 (0%)	1/2 (50%)	0/2 (0%)
FIRST INCIDENCE	660	---	684	616

STATISTICAL TESTS

POLY 3	P=0.254N	P=0.002N**	P=0.549N	P=0.280N
POLY 1.5	P=0.290N	P<0.001N**	P=0.525N	P=0.259N
POLY 6	P=0.240N	P=0.064N	P=0.593N	P=0.316N
COCH-ARM / FISHERS	P=0.357N	P=0.200N	P=0.500N	P=0.250N
MAX-ISO-POLY-3	P=0.098N	P<0.001N**	P=0.218N	P=0.052N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Bronchial
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/1 (0%)	0/4 (0%)	0/5 (0%)	0/7 (0%)
POLY-3 RATE (b)	0/0.74	0/2.78	0/4.22	0/5.19
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/1 (0%)	0/2 (0%)	0/2 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mediastinal
Angiectasis**

LESION RATES

OVERALL (a)	0/34 (0%)	0/30 (0%)	2/31 (6%)	2/28 (7%)
POLY-3 RATE (b)	0/31.29	0/27.57	2/28.22	2/21.23
POLY-3 PERCENT (g)	0%	0%	7.1%	9.4%
TERMINAL (d)	0/25 (0%)	0/22 (0%)	1/23 (4%)	2/14 (14%)
FIRST INCIDENCE	---	---	451	730 (T)

STATISTICAL TESTS

POLY 3	P=0.041*	(e)	P=0.213	P=0.157
POLY 1.5	P=0.047*	(e)	P=0.214	P=0.166
POLY 6	P=0.036*	(e)	P=0.212	P=0.147
COCH-ARM / FISHERS	P=0.065	(e)	P=0.224	P=0.200
MAX-ISO-POLY-3	P=0.064	(e)	P=0.070	P=0.063

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Lymph Node, Mediastinal Hemorrhage

LESION RATES

OVERALL (a)	0/34 (0%)	0/30 (0%)	0/31 (0%)	2/28 (7%)
POLY-3 RATE (b)	0/31.29	0/27.57	0/27.46	2/22.23
POLY-3 PERCENT (g)	0%	0%	0%	9%
TERMINAL (d)	0/25 (0%)	0/22 (0%)	0/23 (0%)	1/14 (7%)
FIRST INCIDENCE	---	---	---	38

STATISTICAL TESTS

POLY 3	P=0.031*	(e)	(e)	P=0.165
POLY 1.5	P=0.032*	(e)	(e)	P=0.174
POLY 6	P=0.030*	(e)	(e)	P=0.155
COCH-ARM / FISHERS	P=0.036*	(e)	(e)	P=0.200
MAX-ISO-POLY-3	P=0.024*	(e)	(e)	P=0.063

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mediastinal
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/34 (0%)	0/30 (0%)	0/31 (0%)	0/28 (0%)
POLY-3 RATE (b)	0/31.29	0/27.57	0/27.46	0/21.23
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/25 (0%)	0/22 (0%)	0/23 (0%)	0/14 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node, Mesenteric
Angiectasis**

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.10	0/43.56	0/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Lymph Node: Pancreatic
 Angiectasis**

LESION RATES

OVERALL (a)	0/1 (0%)	0/3 (0%)	0/2 (0%)	0/2 (0%)
POLY-3 RATE (b)	0/1.00	0/2.47	0/1.41	0/1.82
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Mammary Gland
Galactocele**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	1/45.31	0/43.77	3/42.62	1/37.90
POLY-3 PERCENT (g)	2.2%	0%	7%	2.6%
TERMINAL (d)	1/34 (3%)	0/33 (0%)	2/30 (7%)	0/24 (0%)
FIRST INCIDENCE	730 (T)	---	694	660

STATISTICAL TESTS

POLY 3	P=0.380	P=0.507N	P=0.283	P=0.719
POLY 1.5	P=0.407	P=0.504N	P=0.292	P=0.733
POLY 6	P=0.353	P=0.510N	P=0.273	P=0.705
COCH-ARM / FISHERS	P=0.469	P=0.500N	P=0.309	P=0.753N
MAX-ISO-POLY-3	P=0.281	P=0.167N	P=0.146	P=0.452

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Mesentery
Necrosis**

LESION RATES

OVERALL (a)	13/13 (100%)	26/26 (100%)	16/17 (94%)	22/23 (96%)
POLY-3 RATE (b)	13/13.00	26/26.00	16/16.42	22/22.50
POLY-3 PERCENT (g)	100%	100%	97.4%	97.8%
TERMINAL (d)	10/10 (100%)	20/20 (100%)	10/10 (100%)	12/12 (100%)
FIRST INCIDENCE	438	575	417	453

STATISTICAL TESTS

POLY 3	P=0.464N	(e)	P=0.929N	P=0.904N
POLY 1.5	P=0.354N	(e)	P=0.745N	P=0.761N
POLY 6	P=0.841N	(e)	P=1.000N	P=1.000N
COCH-ARM / FISHERS	P=0.287N	(e)	P=0.567N	P=0.639N
MAX-ISO-POLY-3	P=0.338N	(e)	P=0.204N	P=0.253N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Nose
Foreign Body

LESION RATES

OVERALL (a)	6/50 (12%)	6/50 (12%)	6/49 (12%)	9/50 (18%)
POLY-3 RATE (b)	6/45.64	6/45.02	6/41.71	9/40.65
POLY-3 PERCENT (g)	13.2%	13.3%	14.4%	22.1%
TERMINAL (d)	5/34 (15%)	2/33 (6%)	5/30 (17%)	5/24 (21%)
FIRST INCIDENCE	639	575	718	142

STATISTICAL TESTS

POLY 3	P=0.144	P=0.611	P=0.557	P=0.207
POLY 1.5	P=0.166	P=0.614	P=0.577	P=0.234
POLY 6	P=0.120	P=0.612	P=0.532	P=0.178
COCH-ARM / FISHERS	P=0.210	P=0.620N	P=0.606	P=0.288
MAX-ISO-POLY-3	P=0.225	P=0.489	P=0.434	P=0.148

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose
Inflammation Chronic**

LESION RATES

OVERALL (a)	24/50 (48%)	38/50 (76%)	40/49 (82%)	43/50 (86%)
POLY-3 RATE (b)	24/47.26	38/47.41	40/48.15	43/48.34
POLY-3 PERCENT (g)	50.8%	80.2%	83.1%	89%
TERMINAL (d)	17/34 (50%)	27/33 (82%)	23/30 (77%)	20/24 (83%)
FIRST INCIDENCE	493	433	417	142

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.002**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.004**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Epithelium
 Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	48/50 (96%)	48/50 (96%)	48/49 (98%)	47/50 (94%)
POLY-3 RATE (b)	48/49.67	48/49.38	48/48.24	47/48.01
POLY-3 PERCENT (g)	96.6%	97.2%	99.5%	97.9%
TERMINAL (d)	33/34 (97%)	32/33 (97%)	30/30 (100%)	23/24 (96%)
FIRST INCIDENCE	438	433	417	386

STATISTICAL TESTS

POLY 3	P=0.418	P=0.673	P=0.370	P=0.598
POLY 1.5	P=0.405	P=0.679	P=0.414	P=0.581
POLY 6	P=0.485	P=0.682	P=0.368	P=0.655
COCH-ARM / FISHERS	P=0.403N	P=0.691N	P=0.508	P=0.500N
MAX-ISO-POLY-3	P=0.374	P=0.429	P=0.128	P=0.348

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Glands
Hyperplasia**

LESION RATES

OVERALL (a)	6/50 (12%)	23/50 (46%)	28/49 (57%)	30/50 (60%)
POLY-3 RATE (b)	6/46.06	23/46.65	28/46.66	30/44.92
POLY-3 PERCENT (g)	13%	49.3%	60%	66.8%
TERMINAL (d)	3/34 (9%)	15/33 (46%)	14/30 (47%)	11/24 (46%)
FIRST INCIDENCE	639	491	417	431

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	3/50 (6%)	4/50 (8%)	6/49 (12%)	9/50 (18%)
POLY-3 RATE (b)	3/45.31	4/44.63	6/42.64	9/39.80
POLY-3 PERCENT (g)	6.6%	9%	14.1%	22.6%
TERMINAL (d)	3/34 (9%)	1/33 (3%)	2/30 (7%)	6/24 (25%)
FIRST INCIDENCE	730 (T)	575	541	142

STATISTICAL TESTS

POLY 3	P=0.014*	P=0.492	P=0.212	P=0.034*
POLY 1.5	P=0.018*	P=0.494	P=0.220	P=0.041*
POLY 6	P=0.011*	P=0.492	P=0.205	P=0.026*
COCH-ARM / FISHERS	P=0.028*	P=0.500	P=0.233	P=0.061
MAX-ISO-POLY-3	P=0.021*	P=0.341	P=0.131	P=0.022*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	13/50 (26%)	9/49 (18%)	18/50 (36%)
POLY-3 RATE (b)	5/45.31	13/45.20	9/41.89	18/42.19
POLY-3 PERCENT (g)	11%	28.8%	21.5%	42.7%
TERMINAL (d)	5/34 (15%)	7/33 (21%)	7/30 (23%)	10/24 (42%)
FIRST INCIDENCE	730 (T)	575	684	142

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.030*	P=0.149	P<0.001**
POLY 1.5	P=0.002**	P=0.030*	P=0.162	P<0.001**
POLY 6	P<0.001**	P=0.030*	P=0.136	P<0.001**
COCH-ARM / FISHERS	P=0.004**	P=0.033*	P=0.183	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.016*	P=0.098	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Nose: Respiratory Epithelium
Metaplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	5/49 (10%)	1/50 (2%)
POLY-3 RATE (b)	1/45.57	1/43.77	5/42.43	1/38.03
POLY-3 PERCENT (g)	2.2%	2.3%	11.8%	2.6%
TERMINAL (d)	0/34 (0%)	1/33 (3%)	3/30 (10%)	0/24 (0%)
FIRST INCIDENCE	660	730 (T)	541	619

STATISTICAL TESTS

POLY 3	P=0.372	P=0.752	P=0.085	P=0.719
POLY 1.5	P=0.411	P=0.755	P=0.090	P=0.733
POLY 6	P=0.331	P=0.748	P=0.080	P=0.703
COCH-ARM / FISHERS	P=0.499	P=0.753N	P=0.098	P=0.753N
MAX-ISO-POLY-3	P=0.244	P=0.488	P=0.040*	P=0.452

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
Foreign Body**

LESION RATES

OVERALL (a)	0/2 (0%)	0/0 (0%)	1/1 (100%)	1/1 (100%)
POLY-3 RATE (b)	0/2.00	0/0.00	1/1.00	1/1.00
POLY-3 PERCENT (g)	0%	0%	100%	100%
TERMINAL (d)	0/2 (0%)	0/0 (0%)	1/1 (100%)	1/1 (100%)
FIRST INCIDENCE	---	---	730 (T)	730 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	P=0.333	P=0.333
POLY 1.5	(e)	(e)	P=0.333	P=0.333
POLY 6	(e)	(e)	P=0.333	P=0.333
COCH-ARM / FISHERS	P=0.114	(e)	P=0.333	P=0.333
MAX-ISO-POLY-3	(e)	(e)	P<0.001**	P<0.001**

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
 Hyperplasia**

LESION RATES

OVERALL (a)	2/2 (100%)	0/0 (0%)	1/1 (100%)	1/1 (100%)
POLY-3 RATE (b)	2/2.00	0/0.00	1/1.00	1/1.00
POLY-3 PERCENT (g)	100%	0%	100%	100%
TERMINAL (d)	2/2 (100%)	0/0 (0%)	1/1 (100%)	1/1 (100%)
FIRST INCIDENCE	730 (T)	---	730 (T)	730 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Oral Mucosa
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/2 (0%)	0/0 (0%)	0/1 (0%)	1/1 (100%)
POLY-3 RATE (b)	0/2.00	0/0.00	0/1.00	1/1.00
POLY-3 PERCENT (g)	0%	0%	0%	100%
TERMINAL (d)	0/2 (0%)	0/0 (0%)	0/1 (0%)	1/1 (100%)
FIRST INCIDENCE	---	---	---	730 (T)

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	P=0.333
POLY 1.5	(e)	(e)	(e)	P=0.333
POLY 6	(e)	(e)	(e)	P=0.333
COCH-ARM / FISHERS	P=0.148	(e)	(e)	P=0.333
MAX-ISO-POLY-3	(e)	(e)	(e)	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Ovary
Cyst**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	3/45.49	1/43.77	7/43.11	3/37.64
POLY-3 PERCENT (g)	6.6%	2.3%	16.2%	8%
TERMINAL (d)	2/34 (6%)	1/33 (3%)	4/30 (13%)	3/24 (13%)
FIRST INCIDENCE	683	730 (T)	607	730 (T)

STATISTICAL TESTS

POLY 3	P=0.261	P=0.319N	P=0.135	P=0.572
POLY 1.5	P=0.300	P=0.314N	P=0.144	P=0.602
POLY 6	P=0.221	P=0.325N	P=0.125	P=0.537
COCH-ARM / FISHERS	P=0.389	P=0.309N	P=0.159	P=0.661N
MAX-ISO-POLY-3	P=0.188	P=0.169N	P=0.080	P=0.412

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Pancreas: Acinus Atrophy

LESION RATES

OVERALL (a)	9/50 (18%)	12/50 (24%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	9/45.31	12/44.60	7/43.41	7/38.91
POLY-3 PERCENT (g)	19.9%	26.9%	16.1%	18%
TERMINAL (d)	9/34 (27%)	9/33 (27%)	4/30 (13%)	4/24 (17%)
FIRST INCIDENCE	730 (T)	575	554	529

STATISTICAL TESTS

POLY 3	P=0.330N	P=0.294	P=0.428N	P=0.524N
POLY 1.5	P=0.294N	P=0.301	P=0.415N	P=0.484N
POLY 6	P=0.367N	P=0.291	P=0.442N	P=0.563N
COCH-ARM / FISHERS	P=0.216N	P=0.312	P=0.393N	P=0.393N
MAX-ISO-POLY-3	P=0.408N	P=0.217	P=0.327N	P=0.418N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Parathyroid Gland
Hyperplasia**

LESION RATES

OVERALL (a)	0/47 (0%)	0/48 (0%)	0/47 (0%)	0/46 (0%)
POLY-3 RATE (b)	0/42.31	0/41.93	0/40.48	0/34.46
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/32 (0%)	0/29 (0%)	0/22 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Pituitary Gland
Cyst**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/45.37	1/43.77	2/42.83	2/38.68
POLY-3 PERCENT (g)	4.4%	2.3%	4.7%	5.2%
TERMINAL (d)	1/34 (3%)	1/33 (3%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	716	730 (T)	680	501

STATISTICAL TESTS

POLY 3	P=0.461	P=0.513N	P=0.673	P=0.635
POLY 1.5	P=0.480	P=0.507N	P=0.681	P=0.653
POLY 6	P=0.441	P=0.518N	P=0.664	P=0.616
COCH-ARM / FISHERS	P=0.526	P=0.500N	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.556	P=0.294N	P=0.476	P=0.439

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Pituitary Gland
 Hemorrhage**

LESION RATES

OVERALL (a)	2/50 (4%)	4/50 (8%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	2/45.31	4/43.77	5/43.46	3/38.74
POLY-3 PERCENT (g)	4.4%	9.1%	11.5%	7.7%
TERMINAL (d)	2/34 (6%)	4/33 (12%)	3/30 (10%)	1/24 (4%)
FIRST INCIDENCE	730 (T)	730 (T)	541	529

STATISTICAL TESTS

POLY 3	P=0.350	P=0.321	P=0.199	P=0.429
POLY 1.5	P=0.383	P=0.328	P=0.206	P=0.450
POLY 6	P=0.318	P=0.314	P=0.191	P=0.407
COCH-ARM / FISHERS	P=0.463	P=0.339	P=0.218	P=0.500
MAX-ISO-POLY-3	P=0.338	P=0.192	P=0.112	P=0.278

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	7/50 (14%)	11/50 (22%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	7/46.05	11/44.86	7/43.06	7/38.07
POLY-3 PERCENT (g)	15.2%	24.5%	16.3%	18.4%
TERMINAL (d)	4/34 (12%)	8/33 (24%)	5/30 (17%)	6/24 (25%)
FIRST INCIDENCE	633	528	618	606

STATISTICAL TESTS

POLY 3	P=0.523	P=0.197	P=0.561	P=0.462
POLY 1.5	P=0.514N	P=0.205	P=0.583	P=0.512
POLY 6	P=0.454	P=0.188	P=0.535	P=0.406
COCH-ARM / FISHERS	P=0.397N	P=0.218	P=0.613N	P=0.613N
MAX-ISO-POLY-3	P=0.497	P=0.135	P=0.446	P=0.360

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Salivary Glands
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	1/38.11
POLY-3 PERCENT (g)	0%	0%	0%	2.6%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	590

STATISTICAL TESTS

POLY 3	P=0.179	(e)	(e)	P=0.466
POLY 1.5	P=0.185	(e)	(e)	P=0.476
POLY 6	P=0.173	(e)	(e)	P=0.454
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

TDMS No. 20011 - 05
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 1-Bromopropane
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008
 Time Report Requested: 10:20:06
 First Dose M/F: 07/14/03 / 07/14/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Skin
 Hyperkeratosis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/45.31	2/43.77	2/42.65	0/37.64
POLY-3 PERCENT (g)	2.2%	4.6%	4.7%	0%
TERMINAL (d)	1/34 (3%)	2/33 (6%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	730 (T)	730 (T)	684	---

STATISTICAL TESTS

POLY 3	P=0.367N	P=0.488	P=0.479	P=0.537N
POLY 1.5	P=0.344N	P=0.493	P=0.487	P=0.525N
POLY 6	P=0.393N	P=0.483	P=0.469	P=0.550N
COCH-ARM / FISHERS	P=0.296N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.291N	P=0.273	P=0.269	P=0.203N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/45.31	3/43.93	1/42.47	1/37.64
POLY-3 PERCENT (g)	2.2%	6.8%	2.4%	2.7%
TERMINAL (d)	1/34 (3%)	2/33 (6%)	1/30 (3%)	1/24 (4%)
FIRST INCIDENCE	730 (T)	687	730 (T)	730 (T)

STATISTICAL TESTS

POLY 3	P=0.510N	P=0.294	P=0.746	P=0.718
POLY 1.5	P=0.489N	P=0.299	P=0.752	P=0.732
POLY 6	P=0.535N	P=0.290	P=0.739	P=0.701
COCH-ARM / FISHERS	P=0.444N	P=0.309	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.526N	P=0.150	P=0.481	P=0.451

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Fibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	0/37.64
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	33/50 (66%)	32/50 (64%)	29/50 (58%)	21/50 (42%)
POLY-3 RATE (b)	33/47.62	32/45.28	29/43.77	21/39.08
POLY-3 PERCENT (g)	69.3%	70.7%	66.3%	53.7%
TERMINAL (d)	27/34 (79%)	26/33 (79%)	23/30 (77%)	16/24 (67%)
FIRST INCIDENCE	438	577	547	578

STATISTICAL TESTS

POLY 3	P=0.057N	P=0.534	P=0.463N	P=0.093N
POLY 1.5	P=0.028N*	P=0.585	P=0.379N	P=0.051N
POLY 6	P=0.112N	P=0.487	P=0.566N	P=0.161N
COCH-ARM / FISHERS	P=0.006N**	P=0.500N	P=0.268N	P=0.013N*
MAX-ISO-POLY-3	P=0.089N	P=0.440	P=0.376N	P=0.077N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Hemorrhage Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/45.64	0/43.77	1/43.07	2/37.82
POLY-3 PERCENT (g)	2.2%	0%	2.3%	5.3%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	639	---	541	682

STATISTICAL TESTS

POLY 3	P=0.211	P=0.508N	P=0.748	P=0.435
POLY 1.5	P=0.222	P=0.505N	P=0.753	P=0.456
POLY 6	P=0.200	P=0.512N	P=0.741	P=0.412
COCH-ARM / FISHERS	P=0.247	P=0.500N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.210	P=0.169N	P=0.483	P=0.247

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Infarct Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/45.37	1/43.77	1/42.65	1/37.80
POLY-3 PERCENT (g)	2.2%	2.3%	2.3%	2.7%
TERMINAL (d)	0/34 (0%)	1/33 (3%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	716	730 (T)	684	688

STATISTICAL TESTS

POLY 3	P=0.570	P=0.753	P=0.747	P=0.718
POLY 1.5	P=0.590	P=0.756	P=0.752	P=0.732
POLY 6	P=0.548	P=0.749	P=0.740	P=0.703
COCH-ARM / FISHERS	P=0.634	P=0.753N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.692	P=0.489	P=0.482	P=0.451

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Spleen
Inflammation Granulomatous**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/45.31	2/43.77	0/42.47	0/37.64
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/34 (0%)	2/33 (6%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	730 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.442N	P=0.229	(e)	(e)
POLY 1.5	P=0.429N	P=0.233	(e)	(e)
POLY 6	P=0.457N	P=0.226	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.317N	P=0.076	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/46.08	0/43.77	2/42.65	2/38.91
POLY-3 PERCENT (g)	8.7%	0%	4.7%	5.1%
TERMINAL (d)	1/34 (3%)	0/33 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	633	---	684	386

STATISTICAL TESTS

POLY 3	P=0.436N	P=0.067N	P=0.373N	P=0.418N
POLY 1.5	P=0.427N	P=0.064N	P=0.358N	P=0.391N
POLY 6	P=0.448N	P=0.071N	P=0.393N	P=0.450N
COCH-ARM / FISHERS	P=0.404N	P=0.059N	P=0.339N	P=0.339N
MAX-ISO-POLY-3	P=0.219N	P=0.025N*	P=0.237N	P=0.281N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	2/45.67	3/45.01	3/43.20	6/40.12
POLY-3 PERCENT (g)	4.4%	6.7%	6.9%	15%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	647	433	554	386

STATISTICAL TESTS

POLY 3	P=0.055	P=0.493	P=0.475	P=0.094
POLY 1.5	P=0.062	P=0.496	P=0.485	P=0.105
POLY 6	P=0.048*	P=0.490	P=0.462	P=0.084
COCH-ARM / FISHERS	P=0.080	P=0.500	P=0.500	P=0.134
MAX-ISO-POLY-3	P=0.073	P=0.319	P=0.306	P=0.056

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Stomach, Glandular
Ulcer**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	3/46.05	1/43.93	1/43.05	1/38.03
POLY-3 PERCENT (g)	6.5%	2.3%	2.3%	2.6%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	633	687	547	619

STATISTICAL TESTS

POLY 3	P=0.270N	P=0.322N	P=0.330N	P=0.377N
POLY 1.5	P=0.261N	P=0.315N	P=0.319N	P=0.353N
POLY 6	P=0.280N	P=0.330N	P=0.343N	P=0.404N
COCH-ARM / FISHERS	P=0.242N	P=0.309N	P=0.309N	P=0.309N
MAX-ISO-POLY-3	P=0.290N	P=0.172N	P=0.179N	P=0.226N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Thyroid Gland: C-Cell
Hyperplasia**

LESION RATES

OVERALL (a)	39/50 (78%)	36/50 (72%)	37/50 (74%)	37/50 (74%)
POLY-3 RATE (b)	39/47.92	36/45.51	37/45.78	37/44.21
POLY-3 PERCENT (g)	81.4%	79.1%	80.8%	83.7%
TERMINAL (d)	30/34 (88%)	28/33 (85%)	26/30 (87%)	20/24 (83%)
FIRST INCIDENCE	438	575	451	386

STATISTICAL TESTS

POLY 3	P=0.393	P=0.493N	P=0.583N	P=0.493
POLY 1.5	P=0.449	P=0.422N	P=0.512N	P=0.555
POLY 6	P=0.362	P=0.564N	P=0.592	P=0.458
COCH-ARM / FISHERS	P=0.424N	P=0.322N	P=0.408N	P=0.408N
MAX-ISO-POLY-3	P=0.526	P=0.385N	P=0.470N	P=0.380

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Thyroid Gland: Follicular Cell
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/45.31	1/43.77	2/42.67	0/37.64
POLY-3 PERCENT (g)	0%	2.3%	4.7%	0%
TERMINAL (d)	0/34 (0%)	1/33 (3%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	---	730 (T)	680	---

STATISTICAL TESTS

POLY 3	P=0.589	P=0.493	P=0.224	(e)
POLY 1.5	P=0.622	P=0.496	P=0.229	(e)
POLY 6	P=0.551	P=0.490	P=0.218	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.356	P=0.158	P=0.076	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Trachea
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	1/50 (2%)	6/50 (12%)
POLY-3 RATE (b)	0/45.31	4/44.90	1/42.47	6/39.91
POLY-3 PERCENT (g)	0%	8.9%	2.4%	15%
TERMINAL (d)	0/34 (0%)	2/33 (6%)	1/30 (3%)	2/24 (8%)
FIRST INCIDENCE	---	528	730 (T)	431

STATISTICAL TESTS

POLY 3	P=0.012*	P=0.059	P=0.487	P=0.010**
POLY 1.5	P=0.014*	P=0.060	P=0.492	P=0.011*
POLY 6	P=0.010**	P=0.059	P=0.481	P=0.008**
COCH-ARM / FISHERS	P=0.020*	P=0.059	P=0.500	P=0.013*
MAX-ISO-POLY-3	P=0.005**	P=0.019*	P=0.158	P=0.004**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Trachea: Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	4/38.74
POLY-3 PERCENT (g)	0%	0%	0%	10.3%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	2/24 (8%)
FIRST INCIDENCE	---	---	---	529

STATISTICAL TESTS

POLY 3	P=0.002**	(e)	(e)	P=0.043*
POLY 1.5	P=0.002**	(e)	(e)	P=0.048*
POLY 6	P=0.002**	(e)	(e)	P=0.038*
COCH-ARM / FISHERS	P=0.003**	(e)	(e)	P=0.059
MAX-ISO-POLY-3	P=0.003**	(e)	(e)	P=0.019*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Uterus
Decidual Reaction**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/45.31	0/43.77	0/42.47	2/38.32
POLY-3 PERCENT (g)	0%	0%	0%	5.2%
TERMINAL (d)	0/34 (0%)	0/33 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	---	---	501

STATISTICAL TESTS

POLY 3	P=0.040*	(e)	(e)	P=0.202
POLY 1.5	P=0.041*	(e)	(e)	P=0.213
POLY 6	P=0.038*	(e)	(e)	P=0.191
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

**Uterus
Hemorrhage**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/45.31	2/44.20	0/42.47	1/37.64
POLY-3 PERCENT (g)	0%	4.5%	0%	2.7%
TERMINAL (d)	0/34 (0%)	1/33 (3%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	603	---	730 (T)

STATISTICAL TESTS

POLY 3	P=0.474	P=0.232	(e)	P=0.463
POLY 1.5	P=0.496	P=0.234	(e)	P=0.475
POLY 6	P=0.451	P=0.230	(e)	P=0.450
COCH-ARM / FISHERS	P=0.539	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.332	P=0.076	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	125 PPM	250 PPM	500 PPM

Vagina: Muscularis Hypertrophy

LESION RATES

OVERALL (a)	2/3 (67%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	2/2.31	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	86.7%	0%	0%	0%
TERMINAL (d)	2/2 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	730 (T)	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=1.000N	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***